

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/035010 A2

(51) International Patent Classification⁷:

A61K

(21) International Application Number:

PCT/US2003/008880

(22) International Filing Date: 21 March 2003 (21.03.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/367,089	22 March 2002 (22.03.2002)	US
60/367,863	25 March 2002 (25.03.2002)	US
60/368,618	29 March 2002 (29.03.2002)	US
60/451,824	3 March 2003 (03.03.2003)	US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

(71) Applicant (*for all designated States except US*): BASF AKTIENGESELLSCHAFT [DE/DE]; 67056 Ludwigshafen (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): YOCUM, Rogers, R. [US/US]; 4 Orchard Lane, Lexington, MA 02420 (US). WILLIAMS, Mark, K. [US/US]; 58 School Street, Revere, MA 02151 (US). PERO, Janice, G. [US/US]; 20 Solomon Pierce Road, Lexington, MA 02420 (US).

(74) Agents: HANLEY, Elizabeth, A. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).

(48) Date of publication of this corrected version:

10 June 2004

(15) Information about Correction:

see PCT Gazette No. 24/2004 of 10 June 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS

(57) Abstract: The present invention features methods of producing B6 vitamers that involve culturing an organism overexpressing an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer under conditions such that a B6 vitamer is produced. The present invention further features methods of producing B6 vitamers that involve culturing recombinant microorganisms having increased activity of at least one B6 vitamer biosynthetic enzyme, e.g., YaaD or YaaE, or a homologue thereof, or Epd, PdxA, PdxJ, PdxF, PdxB, PdxH, and/or Dxs, or a homologue thereof.



WO 2004/035010 A2

Rec'd PCT/PTO 22 SEP 2004

10/508768

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/035010 A2

(51) International Patent Classification⁷:

A61K

(74) Agents: HANLEY, Elizabeth, A. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).

(21) International Application Number:

PCT/US2003/008880

(22) International Filing Date: 21 March 2003 (21.03.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/367,089	22 March 2002 (22.03.2002)	US
60/367,863	25 March 2002 (25.03.2002)	US
60/368,618	29 March 2002 (29.03.2002)	US
Not furnished	3 March 2003 (03.03.2003)	US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): BASF AKTIENGESELLSCHAFT [DE/DE]; 67056 Ludwigshafen (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): YOCUM, Rogers, R. [US/US]; 4 Orchard Lane, Lexington, MA 02420 (US). WILLIAMS, Mark, K. [US/US]; 58 School Street, Revere, MA 02151 (US). PERO, Janice, G. [US/US]; 20 Solomon Pierce Road, Lexington, MA 02420 (US).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS

(57) Abstract: The present invention features methods of producing B6 vitamers that involve culturing an organism overexpressing an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer under conditions such that a B6 vitamer is produced. The present invention further features methods of producing B6 vitamers that involve culturing recombinant microorganisms having increased activity of at least one B6 vitamer biosynthetic enzyme, e.g., YaaD or YaaE, or a homologue thereof, or Epd, PdxA, PdxJ, PdxF, PdxB, PdxH, and/or Dxs, or a homologue thereof.

WO 2004/035010 A2

METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS

5 Related Applications

This application claims priority to U.S. Provisional Application Serial No. (Serial No. not yet received) entitled "METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS" (Atty Ref. No. BGI-152-4), filed on March 3, 2003, U.S. Provisional Application Serial No. 60/367,089 filed on March 22, 2002, U.S. Provisional Application Serial No. 60/367,863 filed on March 25, 2002, and U.S. Provisional Application Serial No. 60/368,618 filed on March 29, 2002. The entire content of the above-referenced applications is incorporated herein by this reference.

15 Background of the Invention

Vitamin B6, also known as pyridoxine or pyridoxol (PN), or one of a number of closely related compounds, is an essential dietary nutrient for most, if not all, animals, while many microorganisms (bacteria, fungi, algae, etc.) and plants are capable of synthesizing their own vitamin B6 or compound(s) related to vitamin B6. When an animal ingests PN or a related compound that has vitamin B6 activity, the compound is converted ultimately into pyridoxal phosphate (PLP) and/or pyridoxamine phosphate (PMP), which are the active forms of vitamin B6 in all living organisms. PLP acts as a cofactor for many important or essential enzymes in all living organisms, including transaminases, racemases, and decarboxylases. PLP and PMP are easily interconverted by ubiquitous transaminases.

25 Vitamin B6 is of commercial importance in vitamin pills, pharmaceutical applications, and as an animal feed additive that enhances growth or desirable growth characteristics in farm and domestic animals. The currently used commercial process for producing vitamin B6 is a synthetic chemical process. However, a fermentation process using a microorganism (see US Patent application No. 09/667,569, filed September 21, 2000, hereby incorporated in its entirety by reference) or a biosynthetic process using a plant species can be more cost effective in the long run, and may be environmentally more attractive.

The biosynthetic pathway for PLP in *E. coli* has been elucidated (reviewed in Mittengruber, G., (2001) *J. Mol. Microbiol. Biotechnol.* 3(1): 1-20; Cane, D.E., et al. (2000) *J. Am. Chem. Soc.* 122: 4213-4214; Man, T-K, et al., (1996) *J. Bacteriol.* 178: 2445-2449). Enzymes encoded by the genes *epd*, *pdxB*, *pdxF*, and *pdxA* lead to synthesis of the precursor 1-hydroxy-3-amino acetone phosphate from erythrose-

- 2 -

4-phosphate and glutamate. The enzyme encoded by *dxs* leads to the precursor 5'-deoxyxylulose phosphate from glycolytic intermediates. The enzyme encoded by *pdxJ* then catalyzes the chemical coupling of the two precursors to give pyridoxol phosphate (also called pyridoxine phosphate or PNP). PNP is then oxidized to the active form, PLP, by the enzyme encoded by *pdxH*. This biosynthetic pathway to PLP in *E. coli*, as well as closely related pathways, are referred to herein as the Type A Pathway. Partially characterized mutants of *E. coli* have been described that produce about three- to seven-fold more vitamin B₆-related compounds than the parent strain (Dempsey and Arcement (1971) *J. Bacteriol.* 107(2): 580-582). Partially characterized mutants of *B. subtilis* have been reported that produce 1 - 5 mg/l vitamin B₆, but it was not stated what level the parent strain produced (Pflug, W., and Lingens, F., (1978) *Hoppe-Seyler's Z. Physiol. Chem.* 359: 559-570). Notably, these organisms were not recombinantly produced.

A second biosynthetic pathway for vitamin B₆, referred to herein as the Type B pathway, may exist in some organisms other than *E. coli* (Mittengruber, G., (2001) *J. Mol. Microbiol. Biotechnol.* 3(1):1-20). In particular, some fungi (for example from the genera *Cercospora*, *Neurospora*, *Aspergillus* and *Saccharomyces*), some bacteria (for example *B. subtilis* and *Staphylococcus aureus*), and all plants for which data exists do not contain any genes that are highly homologous to *E. coli* *pdxA* and *pdxJ*. Instead, these organisms contain genes that are homologous to *Cercospora* genes named *SOR* (or *SNZ*) and *SNO*. In *Saccharomyces*, these homologs are called *PDX1* and *PDX2*, respectively, and in *B. subtilis*, these homologs are named *yaaD* and *yaaE*, respectively. Protein or DNA sequence homology alone is not sufficient to establish biological function. For example, *B. subtilis* contains a gene, *yhaF*, that encodes a protein that is significantly homologous to *E. coli* *pdxF*. However, when *yhaF* is mutated, the resulting mutant *B. subtilis* strain is a serine auxotroph, but not a PL auxotroph (see Example 3, below). Thus, the identification of a gene or genes involved in PLP biosynthesis in any given organism can not be done using sequence homology alone. However, the identification of sequence homology between genes, in combination with the presence of one or more common biological activities, may be used to identify homologs of genes involved in PLP biosynthesis.

Results from ¹³C and ¹⁵N labeling studies suggest that the precursors that provide the carbon and nitrogen atoms in PL and related compounds are different in *E. coli* and *Saccharomyces cerevisiae* (Gupta, R., et al. (2001) *J. Am Chem. Soc.* 123: 11353-11359; Tayuza, K., et al. (1995) *Biochim. Biophys. Acta* 1244: 113-116). However, the identity of the precursors for PL and related compounds in *S. cerevisiae* is not yet known. Since most microorganisms for which the entire genome sequence is known (for example *E. coli*, *S. cerevisiae* and *B. subtilis*) have either *pdxA* and *pdxJ*

- 3 -

homologs or *SOR* and *SNO* homologs, but not both, it appears that most organisms that are capable of synthesizing PLP have either the well characterized Type A Pathway (for example *E. coli*, *Salmonella typhimurium*, and many other genera), or a distinctly different and incompletely characterized pathway, *e.g.*, the Type B Pathway.

5 Specifically, members of the genera *Cercospora*, *Neurospora*, *Aspergillus*, *Saccharomyces*, *Bacillus*, *Arabidopsis*, and many other genera, appear to have a Type B pathway, and are lacking some of the genes involved in the Type A Pathway. The intermediate compounds in the Type B Pathway have not yet been elucidated, although the final product must be PLP (as for the Type A Pathway) or PMP, since these are the
10 active forms of vitamin B6 in all known organisms.

Summary of the Invention

The present invention is based, at least in part, on the discovery of key enzyme-encoding genes of the B6 vitamer biosynthetic pathways in, *e.g.*, *Bacillus*
15 *subtilis*. In particular, the invention is based, at least in part, on the discovery that the *yaaD* and *yaaE* genes of *B. subtilis*, or homologues thereof, are required for B6 vitamer synthesis. The invention is further based on the discovery that the biosynthesis of vitamers by an organism can be increased by increasing the level of one or more enzymes involved in B6 vitamer synthesis.

20 Deletion of a portion of the *yaaD* and *yaaE* genes (which are adjacent in an operon, *e.g.*, the *yaaDE* operon) leads to PL auxotrophy. Overexpression of the *yaaDE* operon or the deregulation of the expression of the *yaaD* and *yaaE* genes leads to significantly increased production of B6 vitamers in, *e.g.*, *B. subtilis* strains. The *B. subtilis yaaDE* operon is required for pyridoxal phosphate (PLP) biosynthesis, an active
25 form of vitamin B6 in all living organisms. The present invention describes that the expression of the *B. subtilis yaaDE* operon is a rate limiting step for production of compounds related to vitamin B6 in a wild type strain.

Accordingly, the present invention features methods of producing B6 vitamers, including, but not limited to, pyridoxine (or pyridoxol (PN)), pyridoxal (PL),
30 pyridoxamine (PM), or the 5' phosphorylated derivatives of any of the three aforementioned compounds (PNP, PLP, and PMP), using organisms in which the B6 vitamer pathway has been manipulated such that B6 vitamers are produced. Such methods include culturing an organism, *e.g.*, a microorganism that overexpresses at least one B6 vitamer biosynthetic enzyme under conditions such that the B6 vitamer is
35 produced.

Based on the discovery of the activity of the polypeptides encoded by the *yaaD* and *yaaE* genes, or homologues thereof, in B6 vitamer synthesis, the invention is also based, at least in part, on the discovery that modulation of YaaD and/or YaaE activity (*e.g.*, YaaD and YaaE activity or YaaD activity) results in the modulation of B6 vitamer production. Accordingly, in one aspect, the invention includes a method for producing a B6 vitamer comprising culturing an organism with an increased YaaD and/or YaaE activity (*e.g.*, YaaD and YaaE activity or YaaD activity) as compared to the parent organism. In one embodiment, increased YaaD and/or YaaE activity (*e.g.*, YaaD and YaaE activity or YaaD activity) is due to increased expression of a nucleic acid molecule encoding a YaaD polypeptide and/or YaaE polypeptide (*e.g.*, a YaaD polypeptide and a YaaE polypeptide or a YaaD polypeptide) as compared to an unmodified parent organism. In another embodiment, increased *yaaD* and/or *yaaE* nucleic acid molecule expression (*e.g.*, *yaaD* and *yaaE* nucleic acid expression or *yaaD* nucleic acid expression), is due to the introduction of nucleic acid molecules encoding a YaaD polypeptide and/or a YaaE polypeptide into the organism.

In another aspect, the invention provides methods for producing a B6 vitamer comprising culturing an organism with an increased Epd, PdxA, PdxJ, PdxF, PdxB, PdxH, or Dxs activity as compared to the parent micro. In one embodiment, increased Epd, PdxA, PdxJ, PdxF, PdxB, PdxH, or Dxs activity is due to increased expression of a nucleic acid molecule encoding an Epd, PdxA, PdxJ, PdxF, PdxB, PdxH, and/or a Dxs polypeptide as compared to an unmodified parent organism. In another embodiment, increased *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, and/or *dxs* nucleic acid molecule expression is due to the introduction of nucleic acid molecules encoding an Epd, PdxA, PdxJ, PdxF, PdxB, PdxH, and/or a Dxs polypeptide into the organism.

The production methods of the present invention further can include recovering the B6 vitamer.

The instant invention also features genetically modified organisms, *e.g.*, microorganisms, (*i.e.*, organisms that contain one or more modifications or mutations in the genome) that are capable of producing significantly more of a B6 vitamer than an unmodified parent organism. In particular, this invention features microorganisms (including, for example, but not limited to bacteria, yeasts, fungi, and algae) or macroorganisms such as plants that, when genetically modified, produce an increased amount, *e.g.*, at least about 10-fold more of a B6 vitamer, than the unmodified parent organism. Specific examples are given herein in which *Bacillus subtilis* and *Escherichia coli* strains have been genetically modified such that they produce significant amounts of a B6 vitamer. Accordingly, the present invention features organisms that have been genetically modified to increase the activity of one or more enzymes that catalyze(s) a

- 5 -

step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism.

Yet another aspect of the invention features recombinant organisms, *e.g.*, microorganisms which overexpress at least one *Bacillus* (*e.g.*, *B. subtilis*) B6 vitamer biosynthetic enzyme (*e.g.*, at least one of the *yaaD*, or *yaaE* gene products) or at least one of the *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, and/or *dxs* gene products, are described. In one embodiment, the recombinant microorganism is Gram positive (*e.g.*, microorganisms belonging to the genus *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* or *Streptomyces*). In another embodiment, the recombinant microorganism is Gram negative. Particularly preferred is a *Bacillus* recombinant microorganism (*e.g.*, *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, *Bacillus pumilus*, *Bacillus halodurans*, and the like).

Recombinant vectors that contain genes encoding *Bacillus* B6 vitamer biosynthetic enzymes, *e.g.*, *yaaD* or *yaaE* genes, or homologues thereof, or *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, or *dxs* genes, or homologues thereof, are also described.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings

Figure 1 depicts the chemical structures of vitamin B6 and related compounds.

Figure 2 depicts the biosynthetic pathway for PLP in *E. coli*.

Figure 3 depicts the standard curves generated by *Saccharomyces uvarum* strain ATCC 9080 after feeding serial dilutions of PN, PL, and PM (as described in Example 1).

Figure 4 is a schematic representation of the plasmid pDX1F.

Figure 5 is a schematic representation of the plasmid pDX11F.

Figure 6 is a schematic representation of the plasmid pDX14R.

Figure 7 is a schematic representation of the plasmid pDX17R.

Detailed Description of the Invention

The present invention is based, at least in part, on the identification of *Bacillus* (*e.g.*, *B. subtilis*) genes that encode essential enzymes of the B6 vitamer biosynthetic pathway. In particular, the present invention features methods based on

manipulation of the B6 vitamer biosynthetic pathway in an organism, *e.g.*, a microorganism such that certain desirable compounds are produced.

In particular, the invention is based, at least in part, on the discovery that the *yaaD* and *yaaE* genes of *B. subtilis* are required for B6 vitamer synthesis, including, but not limited to, pyridoxine (or pyridoxol (PN)), pyridoxal (PL), pyridoxamine (PM), or the 5' phosphorylated derivatives of any of the three aforementioned compounds (PNP, PLP, and PMP). The *yaaD* and *yaaE* genes are adjacent on an operon, *e.g.*, the *yaaDE* operon. The *yaaD* and *yaaE* genes encode the YaaD and YaaE proteins, respectively. Accordingly, based on the discovery of the activity of the polypeptides encoded by the *yaaD* and *yaaE* genes, or homologues thereof, in B6 vitamer synthesis, the invention is also based, at least in part, on the discovery that modulation of YaaD and/or YaaE activity results in the modulation of B6 vitamer production.

Accordingly, in one aspect, the invention includes a method for producing a B6 vitamer comprising culturing an organism with an increased YaaD and/or YaaE activity (*e.g.*, YaaD and YaaE activity or YaaD activity) as compared to the parent organism. In one embodiment, increased YaaD and/or YaaE activity (*e.g.*, YaaD and YaaE activity or YaaD activity) is due to increased expression of a nucleic acid molecule encoding a YaaD polypeptide and/or a YaaE polypeptide (*e.g.*, a YaaD polypeptide and a YaaE polypeptide or a YaaD polypeptide) as compared to an unmodified parent organism. In another embodiment, increased *yaaD* and/or *yaaE* nucleic acid molecule expression (*e.g.*, *yaaD* and *yaaE* nucleic acid expression or *yaaD* nucleic acid expression) is due to the introduction of nucleic acid molecules encoding a YaaD polypeptide and/or a YaaE polypeptide (*e.g.*, a YaaD polypeptide and a YaaE polypeptide or a YaaD polypeptide) into the organism. In still another embodiment, the *yaaD* nucleic acid encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:21 and/or the *yaaE* nucleic acid encodes a polypeptide comprising the amino acid sequence SEQ ID NO:23. In still another embodiment, a *yaaD* nucleic acid encodes a polypeptide comprising an amino acid sequence which is at least 30% identical to the amino acid sequence of SEQ ID NO:21, the polypeptide having a YaaD activity. In still another embodiment, a *yaaE* nucleic acid encodes a polypeptide comprising an amino acid sequence which is at least 30% identical to the amino acid sequence of SEQ ID NO:23, the polypeptide having a YaaE activity. In a further embodiment, the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:20 and/or SEQ ID NO:22 is introduced. The nucleotide sequence of *yaaD* is set forth as SEQ ID NO:20 and the nucleotide sequence of *yaaE* is set forth as SEQ ID NO:22.

- 7 -

In another aspect, the invention provides methods for producing a B6 vitamer comprising culturing an organism with an increased *Epd*, *PdxA*, *PdxJ*, *PdxF*, *PdxB*, *PdxH*, and/or *Dxs* activity as compared to the parent organism. In one embodiment, increased *Epd*, *PdxA*, *PdxJ*, *PdxF*, *PdxB*, *PdxH*, and/or *Dxs* activity is due to increased expression of a nucleic acid molecule encoding an *Epd*, *PdxA*, *PdxJ*, *PdxF*, *PdxB*, *PdxH*, and/or a *Dxs* polypeptide as compared to an unmodified parent organism. In another embodiment, increased *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, and/or *dxs* nucleic acid molecule expression is due to the introduction of nucleic acid molecules encoding an *Epd*, *PdxA*, *PdxJ*, *PdxF*, *PdxB*, *PdxH*, and/or a *Dxs* polypeptide into the organism. In still another embodiment, the *pdxA* nucleic acid encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:25 and/or wherein said *pdxJ* nucleic acid encodes a polypeptide comprising the amino acid sequence SEQ ID NO:27. In a further embodiment, the *pdxA* nucleic acid encodes a polypeptide comprising an amino acid sequence which is at least 30% identical to the amino acid sequence of SEQ ID NO:25, the polypeptide having a *PdxA* activity. In still another embodiment, the *pdxJ* nucleic acid encodes a polypeptide comprising an amino acid sequence which is at least 30% identical to the amino acid sequence of SEQ ID NO:27, and having a *PdxJ* activity. In yet another embodiment, the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:24 and/or SEQ ID NO:26 is introduced. The nucleotide sequence of *pdxA* is set forth as SEQ ID NO:24. The nucleotide sequence of *pdxJ* is set forth as SEQ ID NO:26.

Overexpression of the *yaaDE* operon with a strong constitutive promoter or the deregulation of the expression of the *yaaD* or *yaaE* gene(s) leads to significantly increased production of B6 vitamers. These quantities are significantly higher relative to the associated parent strains than those reported in previous studies, which have employed mutant *E. coli* strains (Dempsey and Arcement (1971) *J. Bacteriol.* 107 (2): 580-582), or mutant *B. subtilis* strains (Pflug, W., and Lingens, F., (1978) Hoppe-Seyler's Z. Physiol. Chem. 359: 559-570).

Accordingly, the present invention features organisms, *e.g.*, microorganisms that have been genetically modified to increase the activity of one or more enzymes that catalyze a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from the modified organism is increased compared to B6 production in an unmodified parent organism. In one embodiment, B6 vitamer production is at least ten-fold higher than from the unmodified parent organism. In another embodiment, the organism is genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer, *e.g.*, *yaaD* or *yaaE*, or a homologue thereof, or *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, or *dxs*, or a

homologue thereof. The organism, *e.g.*, microorganism, may be, for example, *B. subtilis* or *E. coli*.

The present invention also features methods of producing a B6 vitamer comprising culturing an organism, *e.g.*, a microorganism that has been genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism, under conditions such that the B6 vitamer is produced. The B6 vitamer may then be subsequently recovered.

The terms "B6 vitamer" or "B6 vitamers," as used herein, shall refer to any compound or mixture of compounds that has any biological activity in any biological assay for vitamin B6. B6 vitamers include, but are not limited to, pyridoxine (also called pyridoxol or PN), pyridoxal (PL), pyridoxamine (PM), the 5' phosphorylated derivatives of any of the three aforementioned compounds (PNP, PLP, and PMP), and any derivative or related compound that can be converted to the active forms (PLP or PMP) in a test organism. Thus, for example, the acetate esters or other esters of any of the available hydroxyl groups of any of the aforementioned six compounds, and which are likely to be hydrolyzed by specific or non-specific esterases, are included in B₆ vitamers. Also, various salts, such as hydrochloride salts, of any of the aforementioned compounds are included in B6 vitamers.

The term "B6 vitamer biosynthetic pathway" includes the biosynthetic pathway involving B6 vitamer biosynthetic enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, precursors, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of B6 vitamers. The term "B6 vitamer biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of B6 vitamers in a microorganism (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of B6 vitamers *in vitro*.

The term "B6 vitamer biosynthetic enzyme" includes an enzyme which is involved in the synthesis of any B6 vitamer in an organism or microorganism, *e.g.*, an enzyme that is rate limiting for B6 vitamer synthesis in said organism or microorganism. B6 vitamer biosynthetic enzymes include, for example, YaaD, YaaE, Epd, PdxA, PdxJ, PdxF, PdxB, PdxH, and/or Dxs, or homologues thereof.

The term "B6 vitamer biosynthetic enzyme activity" includes, for example, any enzyme activity which results in B6 vitamer synthesis. For example, PdxA activity includes the catalysis of hydroxythreonine to hydroxyaminoacetone, and PdxJ activity includes the catalysis of hydroxyaminoacetone and deoxyeylatose to pyridoxol phosphate.

Overproduction or increased activity of the rate limiting enzyme for B6 vitamer production in any organism that is capable of producing B6 vitamers will lead to overproduction of B6 vitamers. For example, overexpression or increased activity of any of the *E. coli* genes involved in the PLP pathway will give a measurable increase in B6 vitamer production. Specifically, overexpression or increased activity of the *E. coli* genes *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, or *dxs*, homologues thereof, or a combination thereof, in *E. coli* may lead to an increase in B6 vitamer production. Moreover, overexpression or increased activity of genes of the type B pathway, e.g., the *yaaD* or *yaaE* genes (e.g., the *yaaD* and *yaaE* genes or the *yaaD* gene) will result in increased B6 vitamer production in host organisms of the type A pathway, e.g., *E. coli*. Likewise, overexpression or increased activity of genes of the type A pathway, e.g., the *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, or *dxs* genes will result in increased B6 vitamer production in host organisms of the type B pathway, e.g., *B. subtilis*.

A "biological assay for a B6 vitamer" includes, for example, any assay that is capable of quantifying B6 vitamer activity by measuring growth of an organism that requires the feeding of a B6 vitamer (i.e., a compound that the fed organism can convert into PLP or PMP) for growth. Samples to be assayed are diluted serially in an appropriate medium and fed to the appropriate organism. Standard curves are generated by serially diluting known amounts of PL, PN, or PM, and feeding these dilutions to the test organism. By comparing dilutions of the unknown samples to the standard curves, total B6 vitamer activity can be determined, for example as PL equivalents if PL was used to generate the standard curve.

Various aspects of the invention are described in further detail in the following subsections.

I. Genes Encoding Various B6 Vitamer Biosynthetic Enzymes

In one embodiment, the present invention features targeting or modifying various biosynthetic genes or enzymes of the B6 vitamer biosynthetic pathway. In particular, the invention features modifying various enzymatic activities associated with said pathways by modifying or altering the genes encoding said biosynthetic enzymes.

The term "gene", as used herein, includes a nucleic acid molecule (e.g., a DNA molecule or segment thereof) that, in an organism, can be separated from another gene or other genes, by intergenic DNA (i.e., intervening or spacer DNA which naturally flanks the gene and/or separates genes in the chromosomal DNA of the organism). Alternatively, a gene may slightly overlap another gene (e.g., the 3' end of a first gene overlapping the 5' end of a second gene), said overlapping genes separated

- 10 -

from other genes by intergenic DNA. A gene may direct synthesis of an enzyme or other protein molecule (*e.g.*, may comprise coding sequences, for example, a contiguous open reading frame (ORF) which encodes a protein) or may itself be functional in the organism. A gene in an organism, may be clustered in an operon, as defined herein, said
5 operon being separated from other genes and/or operons by the intergenic DNA. An “isolated gene”, as used herein, includes a gene which is essentially free of sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived (*i.e.*, is free of adjacent coding sequences which encode a second or distinct protein, adjacent structural sequences or the like) and optionally includes 5' and
10 3' regulatory sequences, for example promoter sequences and/or terminator sequences. In one embodiment, an isolated gene includes predominantly coding sequences for a protein (*e.g.*, sequences which encode *Bacillus* proteins). In another embodiment, an isolated gene includes coding sequences for a protein (*e.g.*, for a *Bacillus* protein) and adjacent 5' and/or 3' regulatory sequences from the chromosomal DNA of the organism
15 from which the gene is derived (*e.g.*, adjacent 5' and/or 3' *Bacillus* regulatory sequences). Preferably, an isolated gene contains less than about 10 kb, 5 kb, 2 kb, 1 kb, 0.5 kb, 0.2 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences that naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived.

The term “operon” includes at least two adjacent genes or ORFs,
20 optionally overlapping in sequence at either the 5' or 3' end of at least one gene or ORF. The term “operon” includes a coordinated unit of gene expression that contains a promoter and possibly a regulatory element associated with one or more adjacent genes or ORFs (*e.g.*, structural genes encoding enzymes, for example, biosynthetic enzymes). Expression of the genes (*e.g.*, structural genes) can be coordinately regulated, for
25 example, by regulatory proteins binding to the regulatory element or by anti-termination of transcription. The genes of an operon (*e.g.*, structural genes) can be transcribed to give a single mRNA that encodes all of the proteins.

A “gene having a mutation” or “mutant gene” as used herein, includes a gene having a nucleotide sequence which includes at least one alteration (*e.g.*,
30 substitution, insertion, deletion) such that the polypeptide or protein encoded by said mutant exhibits an activity that differs from the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. In one embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having an increased activity as compared to the polypeptide or protein encoded by the wild-type gene, for example,
35 when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). As used herein, an “increased activity” or “increased enzymatic activity” is one that is at least 5% greater than that of the polypeptide or protein encoded

by the wild-type nucleic acid molecule or gene, preferably at least 5-10% greater, more preferably at least 10-25% greater and even more preferably at least 25-50%, 50-75% or 75-100% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*,
5 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, an "increased activity" or "increased enzymatic activity" can also include an activity that is at least 1.25-fold greater than the activity of the polypeptide or protein encoded by the wild-type gene, preferably at least 1.5-fold greater, more preferably at least 2-fold greater and even more preferably at least 3-fold,
10 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold or greater than the activity of the polypeptide or protein encoded by the wild-type gene.

In another embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having a reduced activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under
15 similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). A mutant gene also can encode no polypeptide or have a reduced level of production of the wild-type polypeptide. As used herein, a "reduced activity" or "reduced enzymatic activity" is one that is at least 5% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% less, more
20 preferably at least 10-25% less and even more preferably at least 25-50%, 50-75% or 75-100% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, a "reduced activity" or "reduced enzymatic activity" can also include an
25 activity that has been deleted or "knocked out" (*e.g.*, approximately 100% less activity than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene).

Activity can be determined according to any well accepted assay for measuring activity of a particular protein of interest. Activity can be measured or
30 assayed directly, for example, measuring an enzymatic or biological activity of a protein isolated or purified from a cell or microorganism. Alternatively, an activity can be measured or assayed within a cell or microorganism or in an extracellular medium. For example, assaying for a mutant gene (*i.e.*, said mutant encoding a reduced enzymatic activity) can be accomplished by expressing the mutated gene in a microorganism, for
35 example, a mutant microorganism in which the enzyme is temperature-sensitive, and assaying the mutant gene for the ability to complement a temperature sensitive (Ts) mutant for enzymatic activity. A mutant gene that encodes an "increased enzymatic

- 12 -

activity” can be one that complements the Ts mutant more effectively than, for example, a corresponding wild-type gene. A mutant gene that encodes a “reduced enzymatic activity” is one that complements the Ts mutant less effectively than, for example, a corresponding wild-type gene.

5 It will be appreciated by the skilled artisan that even a single substitution in a nucleic acid or gene sequence (*e.g.*, a base substitution that encodes an amino acid change in the corresponding amino acid sequence) can dramatically affect the activity of an encoded polypeptide or protein as compared to the corresponding wild-type polypeptide or protein. A mutant gene (*e.g.*, encoding a mutant polypeptide or protein),
10 as defined herein, is readily distinguishable from a nucleic acid or gene encoding a protein homologue in that a mutant gene encodes a protein or polypeptide having an altered activity, optionally observable as a different or distinct phenotype in an organism expressing said mutant gene or producing said mutant protein or polypeptide (*i.e.*, a mutant microorganism) as compared to a corresponding organism expressing the wild-
15 type gene. By contrast, a protein homologue has an identical or substantially similar activity, optionally phenotypically indiscernible when produced in an organism, *e.g.*, a microorganism, as compared to a corresponding organism, *e.g.*, microorganism, expressing the wild-type gene. Accordingly it is not, for example, the degree of sequence identity between nucleic acid molecules, genes, protein or polypeptides that
20 serves to distinguish between homologues and mutants, rather it is the activity of the encoded protein or polypeptide that distinguishes between homologues and mutants: homologues having, for example, low (*e.g.*, 30-50% sequence identity) sequence identity yet having substantially equivalent functional activities, and mutants, for example sharing 99% sequence identity yet having dramatically different or altered
25 functional activities.

As used herein, the term “homologue”, *e.g.*, a *yaaD*, *yaaE*, *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, or *dxs* homologue, refers to a molecule having at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more nucleotide or amino acid sequence identity to a *yaaD*, *yaaE*,
30 *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, or *dxs* nucleic acid or protein molecule and having a specific functional activity, *e.g.*, a *yaaD* activity, a *yaaE* activity, a *pdxA* activity, or a *pdxJ* activity. A *yaaD* activity, a *yaaE* activity, a *pdxA* activity, or a *pdxJ* activity includes the ability of the homologue to rescue an auxotroph, *e.g.*, an organism which is auxotrophic due to the mutation or deletion of a gene encoding the relevant enzyme
35 involved in a B6 biosynthetic pathway, in a test system, or the ability of the homologue to produce a desired product, *e.g.*, a B6 vitamer or intermediate in the B6 vitamer biosynthetic pathway.

In one embodiment, methods for testing potential homologues, *e.g.*, *yaaD*, *yaaE*, *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, or *dxs* homologues, for a *yaaD*, *yaaE*, *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, or *dxs* functional activity include complementation assays. For example, a complementation assay includes an assay wherein the potential
5 homologue, *e.g.*, a potential homologue isolated from a plant organism or a microorganism, is expressed in an auxotrophic *Bacillus* microorganism in which a portion of the *yaaD* or *yaaE* gene has been deleted, and the ability of the potential homologue to rescue the microorganism from auxotrophy is measured. In one
10 embodiment, a *Bacillus* promoter and ribosome binding site, such as, for example, a ribosome binding site described herein, is utilized for the expression of the homologue in the *Bacillus* microorganism. In another embodiment, the potential homologue is expressed in an auxotrophic *E. coli* microorganism (for example, a *pdxA*, *pdxB*, *pdxF*, *pdxJ*, *dxs*, or *epd* mutant, and the ability of the potential homologue to rescue the microorganism from auxotrophy is measured.

15 A secondary assay for testing potential homologues, *e.g.*, *yaaD*, *yaaE*, *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, or *dxs* homologues, for a *yaaD*, *yaaE*, *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, or *dxs* functional activity includes an assay which directly measures the amount of desired product, *e.g.*, a B6 vitamer, produced by the recombinant organism. For example, the amount of B6 vitamer produced may be
20 measured by methods described herein, *e.g.*, by HPLC analysis, and by other methods known in the art.

A "potential homologue" as used herein, includes a molecule with 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more nucleotide or amino acid sequence identity to a *yaaD*, *yaaE*, *epd*,
25 *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, or *dxs* nucleic acid or protein molecule, where a functional activity of the molecule has not yet been established through, for example, an assay described herein for measuring functional activity.

In a preferred embodiment, the genes of the present invention are derived from *Bacillus*. The term "derived from *Bacillus*" or "*Bacillus*-derived" includes a gene
30 which is naturally found in microorganisms of the genus *Bacillus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus*
35 *megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the gene is derived from *Bacillus brevis* or *Bacillus*

- 14 -

stearothermophilus. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*. In a particularly preferred embodiment, the gene is derived from *Bacillus subtilis* (e.g., is *Bacillus subtilis*-derived). The term “derived from *Bacillus subtilis*” or “*Bacillus subtilis*-derived” includes a gene which is naturally found in the microorganism *Bacillus subtilis*. Included within the scope of the present invention are *Bacillus*-derived genes (e.g., *B. subtilis*-derived genes), for example, *Bacillus* or *B. subtilis yaaD* or *yaaE* genes.

In a preferred embodiment, the genes of the present invention are derived from *Escherichia*. The term “derived from *Escherichia*” or “*Escherichia*-derived” includes a gene which is naturally found in microorganisms of the genus *Escherichia*. In a particularly preferred embodiment, the gene is derived from *Escherichia coli* (e.g., is *Escherichia coli*-derived). The term “derived from *Escherichia coli*” or “*Escherichia coli*-derived” includes a gene which is naturally found in the microorganism *Escherichia coli*. Included within the scope of the present invention are *Escherichia*-derived genes (e.g., *Escherichia coli*-derived genes), for example, *Escherichia* or *Escherichia coli epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, or *dxs* genes.

In another preferred embodiment, the genes of the present invention are derived, for example, from any one of the organisms or microorganisms listed in Section III or in either of Tables 9 or 10 (or in the GenBank records referred to by Accession Nos. listed therein).

II. Recombinant Nucleic Acid Molecules and Vectors

The present invention further features recombinant nucleic acid molecules (e.g., recombinant DNA molecules) that include genes described herein (e.g., isolated genes), preferably *Bacillus* genes, more preferably *Bacillus subtilis* genes, even more preferably *Bacillus subtilis* B6 vitamer biosynthetic genes. The term “recombinant nucleic acid molecule” includes an isolated nucleic acid molecule (e.g., a DNA molecule) that has been altered, modified or engineered such that it differs in nucleotide sequence from the native or natural nucleic acid molecule from which the recombinant nucleic acid molecule was derived (e.g., by addition, deletion or substitution of one or more nucleotides). Preferably, a recombinant nucleic acid molecule (e.g., a recombinant DNA molecule) includes an isolated gene of the present invention operably linked to regulatory sequences. The phrase “operably linked to regulatory sequence(s)” means that the nucleotide sequence of the gene of interest is linked to the regulatory sequence(s) in a manner which allows for expression (e.g., enhanced, increased,

constitutive, basal, attenuated, decreased or repressed expression) of the gene, preferably expression of a gene product encoded by the gene (*e.g.*, when the recombinant nucleic acid molecule is included in a recombinant vector, as defined herein, and is introduced into a microorganism). A "recombinant organism" is any organism that contains a
5 recombinant nucleic acid molecule.

The term "regulatory sequence" includes nucleic acid sequences that affect (*e.g.*, modulate or regulate) expression of other nucleic acid sequences (*i.e.*, genes). In one embodiment, a regulatory sequence is included in a recombinant nucleic acid molecule in a similar or identical position and/or orientation relative to a particular
10 gene of interest as is observed for the regulatory sequence and gene of interest as it appears in nature, *e.g.*, in a native position and/or orientation. For example, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to the gene of interest in the natural organism (*e.g.*, operably linked to "native" regulatory sequences (*e.g.*, to the
15 "native" promoter). Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to another (*e.g.*, a different) gene in the natural organism. Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence from another organism. For example, regulatory sequences from
20 other microbes (*e.g.*, other bacterial regulatory sequences, bacteriophage regulatory sequences and the like) can be operably linked to a particular gene of interest.

In one embodiment, a regulatory sequence is a non-native or non-naturally-occurring sequence (*e.g.*, a sequence which has been modified, mutated, substituted, derivatized, deleted including sequences which are chemically synthesized).
25 Preferred regulatory sequences include promoters, enhancers, termination signals, anti-termination signals, ribosome binding sites and other expression control elements (*e.g.*, sequences to which repressors or inducers bind and/or binding sites for transcriptional and/or translational regulatory proteins, for example, in the transcribed mRNA). Such regulatory sequences are described, for example, in Sambrook, J., Fritsch, E. F., and
30 Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in a microorganism (*e.g.*, constitutive promoters and strong constitutive promoters), those which direct inducible expression of a nucleotide sequence in a
35 microorganism (*e.g.*, inducible promoters, for example, xylose inducible promoters) and those which attenuate or repress expression of a nucleotide sequence in a microorganism (*e.g.*, attenuation signals or repressor sequences). It is also within the scope of the

- 16 -

present invention to regulate expression of a gene of interest by removing or deleting regulatory sequences. For example, sequences involved in the negative regulation of transcription can be removed such that expression of a gene of interest is enhanced.

In one embodiment, a recombinant nucleic acid molecule of the present invention includes a nucleic acid sequence or gene that encodes at least one bacterial gene product (e.g., a B6 vitamers biosynthetic enzyme, e.g., the gene product of *yaaD* and/or *yaaE*, (e.g., the gene product of *yaaD* and *yaaE* or *yaaD*) or a homologue thereof) operably linked to a promoter or promoter sequence. Preferred promoters of the present invention include *Bacillus* promoters and/or bacteriophage promoters (e.g., bacteriophage which infect *Bacillus*). In one embodiment, a promoter is a *Bacillus* promoter, preferably a strong *Bacillus* promoter (e.g., a promoter associated with a biochemical housekeeping gene in *Bacillus* or a promoter associated with a glycolytic pathway gene in *Bacillus*). In another embodiment, a promoter is a bacteriophage promoter. In a preferred embodiment, the promoter is from the bacteriophage SP01. In a particularly preferred embodiment, a promoter is selected from the group consisting of *P₁₅*, *P₂₆*, or *P_{veg}* having for example, the following respective sequences:

GCTATTGACGACAGCTATGGTTCAGTGTCCACCAACCAAACTGTGCTCAGT
 ACCGCCAATATTTCTCCCTTGAGGGGTACAAAGAGGTGTCCCTAGAAGAGAT
 CCACGCTGTGTAAAAATTTTACAAAAAGGTATTGACTTTCCCTACAGGGTGT
 GTAATAATTTAATTACAGGCGGGGGCAACCCCGCCTGT (SEQ ID NO:9),
 GCCTACCTAGCTTCCAAGAAAGATATCCTAACAGCACAAGAGCGGAAAGAT
 GTTTTGTCTACATCCAGAACAACCTCTGCTAAAATTCCTGAAAAATTTTGC
 AAAAAGTTGTTGACTTTATCTACAAGGTGTGGTATAATAATCTTAACAACAG
 CAGGACGC (SEQ ID NO:10); and

GAGGAATCATAGAATTTTGTCAAAATAATTTTATTGACAACGTCTTATTAAC
 GTTGATATAATTTAAATTTTATTGACAAAAATGGGCTCGTGTGTGACAATA
 AATGTAGTGAGGTGGATGCAATG (SEQ ID NO:11). Additional preferred promoters include *tef* (the translational elongation factor (TEF) promoter) and *pyc* (the pyruvate carboxylase (PYC) promoter), which promote high level expression in *Bacillus* (e.g., *Bacillus subtilis*). Additional preferred promoters, for example, for use in Gram positive microorganisms include, but are not limited to, *amy* and SPO2 promoters. Additional preferred promoters, for example, for use in Gram negative microorganisms include, but are not limited to, *tac*, *trp*, *tet*, *trp-tet*, *lpp*, *lac*, *lpp-lac*, *lacIQ*, T7, T5, T3, *gal*, *trc*, *ara*, SP6, λ -PR or λ -PL.

In another embodiment, a recombinant nucleic acid molecule of the present invention includes a terminator sequence or terminator sequences (e.g., transcription terminator sequences). The term "terminator sequences" includes

- 17 -

regulatory sequences that serve to terminate transcription of mRNA. Terminator sequences (or tandem transcription terminators) can further serve to stabilize mRNA (e.g., by adding structure to mRNA), for example, against nucleases.

In yet another embodiment, a recombinant nucleic acid molecule of the present invention includes sequences which allow for detection of the vector containing said sequences (i.e., detectable and/or selectable markers), for example, genes that encode antibiotic resistance or sequences that overcome auxotrophic mutations, for example, *trpC*, fluorescent markers, drug markers, and/or colorimetric markers (e.g., *lacZ*/ β -galactosidase). In yet another embodiment, a recombinant nucleic acid molecule of the present invention includes an artificial ribosome binding site (RBS) or a sequence that becomes transcribed into an artificial RBS. The term "artificial ribosome binding site (RBS)" includes a site within an mRNA molecule (e.g., coded within DNA) to which a ribosome binds (e.g., to initiate translation) which differs from a native RBS (e.g., a RBS found in a naturally-occurring gene) by at least one nucleotide. Preferred artificial RBSs include about 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18, 19-20, 21-22, 23-24, 25-26, 27-28, 29-30 or more nucleotides of which about 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-15 or more differ from the native RBS (e.g., the native RBS of a gene of interest, for example, the native *yaaD* RBS
GAAATCATATAACTATACCTTGATTAGGGGGACCAAGAAATG
(SEQ ID NO:12) or the native *yaaE* RBS
CAAGAACGCGGCTGGTAAGAACATAGGAGCGCTGCTGACATG (SEQ ID NO:13)).

Preferably, nucleotides that differ are substituted such that they are identical to one or more nucleotides of an ideal RBS when optimally aligned for comparisons. Artificial RBSs can be used to replace the naturally-occurring or native RBSs associated with a particular gene. Artificial RBSs preferably increase translation of a particular gene. Preferred artificial RBSs (e.g., RBSs for increasing the translation of *yaaE*, for example, of *B. subtilis*) are set forth in Table 1, below.

Table 1: Preferred Ribosome Binding Sites

		10	20	
				SEQ ID NO:
35	Native_yaaD	---	GAAATCATATAACTATACCTTGATTAGGGGGACC-AAGAAATG	12
	Native_yaaE	CAAGAACGCGGCTGGTAAGAACAT---	AGGAGCGCTGCTGACATG	13
	IDEAL_RBS	-----	TCTAGAAAGG-----AGGTG-----A-----	14
	RBS1	-----	TCTAGAAGG-----AGGAG-----AAAACATG	15
	RBS2	-----	TCTAGAGG-----AGGAG-----AAAACATG	16
40	RBS101	-----	TAAGAACAA-----AGGAGGAGAGCTGACATG	17
	RBS103	-----	TAAGAAGAA-----AGGAGGTGAGCTGACATG	18
	RBS102	-----	TAAGAACAG-----AGGAGGAGAGCTGACATG	19

The present invention further features vectors (*e.g.*, recombinant vectors) that include nucleic acid molecules (*e.g.*, genes or recombinant nucleic acid molecules comprising said genes) as described herein. The term "recombinant vector" includes a vector (*e.g.*, plasmid, phage, phasmid, virus, cosmid or other purified nucleic acid vector) that has been altered, modified or engineered such that it contains greater, fewer or different nucleic acid sequences than those included in the native or natural nucleic acid molecule from which the recombinant vector was derived. Preferably, the recombinant vector includes a biosynthetic enzyme-encoding gene or recombinant nucleic acid molecule including said gene, operably linked to regulatory sequences, for example, promoter sequences, terminator sequences and/or artificial ribosome binding sites (RBSs), as defined herein. In another embodiment, a recombinant vector of the present invention includes sequences that enhance replication in bacteria (*e.g.*, replication-enhancing sequences). In one embodiment, replication-enhancing sequences are derived from *E. coli*. In another embodiment, replication-enhancing sequences are derived from pBR322. In another embodiment, replication-enhancing sequences are derived from pSC101.

In yet another embodiment, a recombinant vector of the present invention includes antibiotic resistance sequences. The term "antibiotic resistance sequences" includes sequences which promote or confer resistance to antibiotics on the host organism (*e.g.*, *Bacillus*). In one embodiment, the antibiotic resistance sequences are selected from the group consisting of *cat* (chloramphenicol resistance) sequences, *tet* (tetracycline resistance) sequences, *erm* (erythromycin resistance) sequences, *neo* (neomycin resistance) sequences, *kan* (kanamycin resistance) and *spec* (spectinomycin resistance) sequences. Recombinant vectors of the present invention can further include homologous recombination sequences (*e.g.*, sequences designed to allow recombination of the gene of interest into the chromosome of the host organism). For example, *bpr*, *vpr*, and/or *amyE* sequences can be used as homology targets for recombination into the host chromosome. It will further be appreciated by one of skill in the art that the design of a vector can be tailored depending on such factors as the choice of microorganism to be genetically engineered, the level of expression of gene product desired and the like.

III. Recombinant Organisms

The present invention further features organisms, *i.e.*, recombinant organisms *e.g.*, recombinant microorganisms, that include vectors or genes (*e.g.*, wild-type and/or mutated genes) as described herein. As used herein, the term "recombinant organism" includes an organism or a microorganism (*e.g.*, bacteria, yeast cell, fungal cell, plant cell, etc.) that has been genetically altered, modified or engineered (*e.g.*,

genetically engineered) such that it exhibits an altered, modified or different genotype and/or phenotype (*e.g.*, when the genetic modification affects coding nucleic acid sequences of the organism) as compared to the naturally-occurring organism from which it was derived, *e.g.*, a wild type or unmodified organism or parent organism or host organism.

Possible host organisms include, for example, plants, algae, fungi, yeasts, and other organisms and microorganisms. The plant may be a monocot, dicot or gymnosperm. Preferred microbes are those used in agriculture or by industry, and those that are pathogenic for plants or animals. Plants include arabidopsis; field crops (*e.g.*, alfalfa, barley, bean, cereals, corn, cotton, flax, lucerne, hemp, millet, oats, pea, rape, rice, rye, safflower, sorghum, soybean, sunflower, tobacco, triticale, and wheat); vegetable crops (*e.g.*, asparagus, beet, broccoli, cabbages, capsicum, carrot, cauliflower, celery, cucumber, eggplant, lettuces, onion, pepper, potato, pumpkin, maize, radish, spinach, squash, taro, tomato, and zucchini); fruit and grapevine and nut species (*e.g.*, almond, apple, apricot, banana, black-berry, blueberry, cacao, cherry, coconut, cranberry, date, fig, filbert, grape, grapefruit, guava, kiwi, lemon, lime, mango, melon, nectarine, orange, papaya, passion fruit, peach, peanut, pear, pineapple, pistachio, plum, raspberry, strawberry, tangerine, walnut, and watermelon); Brassicaceae such as oilseed, canola, sugarbeet, sugarcane; and ornamentals (*e.g.*, alder, ash, aspen, azalea, birch, boxwood, camellia, carnation, chrysanthemum, elm, fir, ivy, jasmine, juniper, oak, palm, poplar, pine, redwood, rhododendron, rose, rubber, and yew).

Fungi which may be used as host organisms include organisms in both the mold and yeast morphologies. Possible fungal host organisms include the phylum *Ascomycota*, including, for example, the subphyla *Neoelectromycetes*, *Pezizomycotina*, *Pneumocystidomycetes*, *Saccharomycotina*, *Schizosaccharomycetes*, *Taphrinomycetes*, *mitosporic Ascomycota*, and unclassified *Ascomycota*; the phylum *Basidiomycota*, including, for example, the subphyla *Hymenomycetes*, *Urediniomycetes*, *Ustilaginomycetes*, *Mitosporic*, *Masidiomycota*, and unclassified *Basidiomycota*; the phylum *Chytridiomycota*, including, for example, the subphyla, *Blastocladales*, *Chytridiales*, *Monoblepharidales*, *Neocallimasticales*, *Spizellomycetales*, and unclassified *Chytridiomycota*; the phylum *Glomeromycota*, including, for example, the subphylum *Glomeromycetes*; the phylum *Microsporidia*, including, for example, the subphyla, *Apansporoblastina*, *Endoreticulatus*, *Gurleyidae*, *Nadelsporidae*, *Ordosporidae*, *Pansporoblastina*, *Pereziiidae*, *Pseudonosematidae*, *Tetramicriidae*, and unclassified *Microsporidia*; the phylum *Zygomycota*, including, for example, the

subphyla, *Trichomycetes*, *Zygomycetes*, and unclassified *Zygomycota* and unclassified Fungi.

Algae which may be used as host organisms include, for example, green algae, red algae, yellow-green algae, Cryptomonads, haptophytes, golden algae,
5 euglenids, diatoms, and brown algae.

Other organisms, e.g., microorganisms, which may be used as host organisms include Gram negative bacteria (e.g., a microorganisms which excludes basic dye, for example, crystal violet) and Gram positive bacteria (e.g., a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-
10 positive wall surrounding the microorganism). Gram negative bacteria include, for example, *Acetobacteriaceae*, *Alcaligenaceae*, *Bacteroidaceae*, *Chromatiaceae*, *Enterobacteriaceae*, *Legionellaceae*, *Neisseriaceae*, *Nitrobacteriaceae*, *Pseudomonadaceae*, *Rhizobiaceae*, *Rickettsiaceae*, *Spirochaetaceae*, *Vibrionaceae*. Gram positive bacteria include, for example, *Bacillaceae*, *Micrococcaceae*, and
15 *Peptococcaceae*.

In a preferred embodiment, the recombinant microorganism is a Gram positive microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the recombinant microorganism is of the genus *Bacillus*. In
20 another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus*
25 species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the recombinant microorganism is *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*.

30 In another preferred embodiment, the recombinant microorganism is a Gram negative microorganism belonging to a genus selected from the group consisting of *Salmonella*, *Escherichia*, *Klebsiella*, *Serratia*, and *Proteus*. In a more preferred embodiment, the recombinant microorganism is of the genus *Escherichia*. In an even more preferred embodiment, the recombinant microorganism is *Escherichia coli*. In
35 another embodiment, the recombinant microorganism is *Saccharomyces* (e.g., *S. cerevisiae*).

- 21 -

A preferred "recombinant" organism, *e.g.*, microorganism of the present invention is an organism, *e.g.*, a microorganism having a deregulated B6 vitamer biosynthesis pathway or enzyme. The term "deregulated" or "deregulation" includes the alteration or modification of at least one gene in an organism, *e.g.*, a microorganism that
5 encodes an enzyme in a biosynthetic pathway, such that the level or activity of the biosynthetic enzyme in the organism, *e.g.*, the microorganism is altered or modified. Preferably, at least one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the gene product is enhanced or increased. The phrase "deregulated pathway" can also include a biosynthetic pathway in which more than one
10 gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the level or activity of more than one biosynthetic enzyme is altered or modified. The ability to "deregulate" a pathway (*e.g.*, to simultaneously deregulate more than one gene in a given biosynthetic pathway) in an organism, *e.g.*, a microorganism in some cases arises from the particular phenomenon of organisms, *e.g.*, microorganisms in which
15 more than one enzyme (*e.g.*, two or three biosynthetic enzymes) are encoded by genes occurring adjacent to one another on a contiguous piece of genetic material termed an "operon" (defined herein). Due to the coordinated regulation of genes included in an operon, alteration or modification of the single promoter and/or regulatory element can result in alteration or modification of the expression of more than one gene product
20 encoded by the operon. Alteration or modification of the regulatory element can include, but is not limited to removing the endogenous promoter and/or regulatory element(s), adding strong promoters, inducible promoters or multiple promoters or removing regulatory sequences such that expression of the gene products is modified, modifying the chromosomal location of the operon, altering nucleic acid sequences
25 adjacent to the operon or within the operon such as a ribosome binding site, increasing the copy number of the operon, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of the operon and/or translation of the gene products of the operon, or any other conventional means of deregulating expression of genes routine in the art (including but
30 not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Deregulation can also involve altering the coding region of one or more genes to yield, for example, an enzyme that is feedback resistant or has a higher or lower specific activity.

In another preferred embodiment, a recombinant organism, *e.g.*,
35 microorganism is designed or engineered such that at least one B6 vitamer biosynthetic enzyme, is overexpressed. The term "overexpressed" or "overexpression" includes expression of a gene product (*e.g.*, a biosynthetic enzyme) at a level greater than that

- 22 -

expressed prior to manipulation of the microorganism or in a comparable organism, *e.g.*, microorganism which has not been manipulated. In one embodiment, the organism, *e.g.*, the microorganism can be genetically designed or engineered to overexpress a level of gene product greater than that expressed in a comparable organism, *e.g.*,

5 microorganism which has not been engineered.

Genetic engineering can include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (*e.g.*, by adding strong promoters, inducible promoters or multiple promoters or by removing regulatory sequences such that expression is constitutive), modifying the

10 chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site, increasing the copy number of a particular gene, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of

15 deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Genetic engineering can also include deletion of a gene, for example, to block a pathway or to remove a repressor. In embodiments featuring organisms having deleted genes, the skilled artisan will appreciate that at least low levels of certain

20 compounds may be required to be present in or added to the culture medium in order that the viability of the organism is not compromised. Often, such low levels are present in complex culture media as routinely formulated. Moreover, in processes featuring culturing organisms having deleted genes cultured under conditions such that commercially or industrially attractive quantities of product are produced, it may be

25 necessary to supplement culture media with slightly increased levels of certain compounds.

In another embodiment, the microorganism can be physically or environmentally manipulated to overexpress a level of gene product greater than that expressed prior to manipulation of the organism or in a comparable microorganism

30 which has not been manipulated. For example, a organism can be treated with or cultured in the presence of an agent known or suspected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased. Alternatively, a organism can be cultured at a temperature selected to increase transcription of a particular gene and/or translation

35 of a particular gene product such that transcription and/or translation are enhanced or increased.

IV. Culturing and Fermenting Recombinant Microorganisms

The term "culturing" includes maintaining and/or growing a living microorganism of the present invention (e.g., maintaining and/or growing a culture or strain). In one embodiment, a microorganism of the invention is cultured in liquid media. In another embodiment, a microorganism of the invention is cultured in solid media or semi-solid media. In a preferred embodiment, a microorganism of the invention is cultured in media (e.g., a sterile, liquid media) comprising nutrients essential or beneficial to the maintenance and/or growth of the microorganism (e.g., carbon sources or carbon substrate, for example carbohydrate, hydrocarbons, oils, fats, fatty acids, organic acids, and alcohols; nitrogen sources, for example, peptone, yeast extracts, meat extracts, malt extracts, soy flour, urea, ammonium sulfate, ammonium chloride, ammonium nitrate and ammonium phosphate; phosphorus sources, for example, phosphoric acid, sodium and potassium salts thereof; trace elements, for example, magnesium, iron, manganese, calcium, copper, zinc, boron, molybdenum, and/or cobalt salts; as well as growth factors such as amino acids, vitamins, and the like).

Preferably, microorganisms of the present invention are cultured under controlled pH. The term "controlled pH" includes any pH which results in production of the desired product. In one embodiment microorganisms are cultured at a pH of about 7. In another embodiment, microorganisms are cultured at a pH of between 6.0 and 8.5. The desired pH may be maintained by any number of methods known to those skilled in the art.

Also preferably, microorganisms of the present invention are cultured under controlled aeration. The term "controlled aeration" includes sufficient aeration (e.g., oxygen) to result in production of the desired product. In one embodiment, aeration is controlled by regulating oxygen levels in the culture, for example, by regulating the amount of oxygen dissolved in culture media. Preferably, aeration of the culture is controlled by agitating the culture. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the culture vessel (e.g., tube or flask) or by various pumping equipment. Aeration may be further controlled by the passage of sterile air or oxygen through the medium (e.g., through the fermentation mixture). Also preferably, microorganisms of the present invention are cultured without excess foaming (e.g., via addition of antifoaming agents).

Moreover, microorganisms of the present invention can be cultured under controlled temperatures. The term "controlled temperature" includes any temperature which results in production of the desired product (e.g., a B6 vitamer). In one embodiment, controlled temperatures include temperatures between 15°C and 95°C. In

- 24 -

another embodiment, controlled temperatures include temperatures between 15°C and 70°C. Preferred temperatures are between 20°C and 55°C, more preferably between 30°C and 50°C.

Microorganisms can be cultured (*e.g.*, maintained and/or grown) in liquid media and preferably are cultured, either continuously or intermittently, by conventional culturing methods such as standing culture, test tube culture, shaking culture (*e.g.*, rotary shaking culture, shake flask culture, etc.), aeration spinner culture, or fermentation. In a preferred embodiment, the microorganisms are cultured in shake flasks. In a more preferred embodiment, the microorganisms are cultured in a fermentor (*e.g.*, a fermentation process). Fermentation processes of the present invention include, but are not limited to, batch, fed-batch and continuous processes or methods of fermentation. The phrase "batch process" or "batch fermentation" refers to a closed system in which the composition of media, nutrients, supplemental additives and the like is set at the beginning of the fermentation and not subject to alteration during the fermentation, however, attempts may be made to control such factors as pH and oxygen concentration to prevent excess media acidification and/or microorganism death. The phrase "fed-batch process" or "fed-batch" fermentation refers to a batch fermentation with the exception that one or more substrates or supplements are added (*e.g.*, added in increments or continuously) as the fermentation progresses. The phrase "continuous process" or "continuous fermentation" refers to a system in which a defined fermentation media is added continuously to a fermentor and an equal amount of used or "conditioned" media is simultaneously removed, preferably for recovery of the desired product (*e.g.*, a B6 vitamer). A variety of such processes have been developed and are well-known in the art.

The phrase "culturing under conditions such that a desired compound is produced" includes maintaining and/or growing microorganisms under conditions (*e.g.*, temperature, pressure, pH, duration, etc.) appropriate or sufficient to obtain production of the desired compound or to obtain desired yields of the particular compound being produced. For example, culturing is continued for a time sufficient to produce the desired amount of a compound (*e.g.*, a B6 vitamer). Preferably, culturing is continued for a time sufficient to substantially reach suitable production of the compound (*e.g.*, a time sufficient to reach a suitable concentration of a B6 vitamer). In one embodiment, culturing is continued for about 12 to 24 hours. In another embodiment, culturing is continued for about 24 to 36 hours, 36 to 48 hours, 48 to 72 hours, 72 to 96 hours, 96 to 120 hours, 120 to 144 hours, or greater than 144 hours. The methodology of the present invention can further include a step of recovering a desired compound (*e.g.*, a B6 vitamer). The term "recovering" a desired compound includes extracting, harvesting,

isolating or purifying the compound from culture media. Recovering the compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (*e.g.*, anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional adsorbent (*e.g.*, activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (*e.g.*, with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization and the like. For example, a compound can be recovered from culture media by first removing the microorganisms from the culture. The resulting solutions are then passed through or over a cation exchange resin to remove cations and/or through or over an anion exchange resin to purify or concentrate the desired product. The resulting compound can subsequently be converted to a salt (*e.g.*, a chloride or sulfate salt) by ion exchange.

Preferably, a desired compound of the present invention is "extracted," "isolated" or "purified" such that the resulting preparation is substantially free of other media components (*e.g.*, free of media components and/or fermentation byproducts). The language "substantially free of other media components" includes preparations of the desired compound in which the compound is separated from media components or fermentation byproducts of the culture from which it is produced. In one embodiment, the preparation has greater than about 80% (by dry weight) of the desired compound (*e.g.*, less than about 20% of other media components or fermentation byproducts), more preferably greater than about 90% of the desired compound (*e.g.*, less than about 10% of other media components or fermentation byproducts), still more preferably greater than about 95% of the desired compound (*e.g.*, less than about 5% of other media components or fermentation byproducts), and most preferably greater than about 98-99% desired compound (*e.g.*, less than about 1-2% other media components or fermentation byproducts). When the desired compound has been derivatized to a salt, the compound is preferably further free of chemical contaminants associated with the formation of the salt. When the desired compound has been derivatized to an alcohol, the compound is preferably further free of chemical contaminants associated with the formation of the alcohol.

In an alternative embodiment, the desired compound is not purified from the microorganism, for example, when the microorganism is biologically non-hazardous (*e.g.*, safe). For example, the entire culture (or culture supernatant) can be used as a source of product (*e.g.*, crude product). In one embodiment, the culture (or culture supernatant) is used without modification. In another embodiment, the culture (or

- 26 -

culture supernatant) is concentrated. In yet another embodiment, the culture (or culture supernatant) is dried or lyophilized.

- Preferably, a production method of the present invention results in production of the desired compound, *e.g.*, a B6 vitamer, at a significantly high yield.
- 5 The phrase "significantly high yield" includes a level of production or yield which is sufficiently elevated or above what is usual for comparable production methods, for example, which is elevated to a level sufficient for commercial production of the desired product (*e.g.*, production of the product at a commercially feasible cost). In one embodiment, the invention features a production method that includes culturing a
- 10 recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 5 mg/L. In another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 10 mg/L. In another embodiment, the invention features
- 15 a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 50 mg/L. In yet another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 150 mg/L.
- 20 Depending on the biosynthetic enzyme or combination of biosynthetic enzymes manipulated, it may be desirable or necessary to provide (*e.g.*, feed) microorganisms of the present invention at least one biosynthetic precursor such that the desired compound or compounds are produced. The term "biosynthetic precursor" or "precursor" includes an agent or compound which, when provided to, brought into
- 25 contact with, or included in the culture medium of a microorganism, serves to enhance or increase biosynthesis of the desired product. In one embodiment, the biosynthetic precursor or precursor is glutamine. In another embodiment, the biosynthetic precursor or precursor is ribose. The amount of glutamine or ribose added is preferably an amount that results in a concentration in the culture medium sufficient to enhance productivity
- 30 of the microorganism (*e.g.*, a concentration sufficient to enhance production of a B6 vitamer). The term "excess ribose or glutamine" includes ribose or glutamine levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples can be done in the presence of about 0-5 g/L ribose or glutamine.
- 35 Accordingly, excess ribose or glutamine levels can include levels of about 5-10 g/L or more preferably about 5-20 g/L ribose or glutamine. Biosynthetic precursors of the present invention can be added in the form of a concentrated solution or suspension

- 27 -

(e.g., in a suitable solvent such as water or buffer) or in the form of a solid (e.g., in the form of a powder). Moreover, biosynthetic precursors of the present invention can be added as a single aliquot, continuously or intermittently over a given period of time.

- Methods for culturing other recombinant organisms, e.g., the
- 5 recombinant plant organisms of the present invention, are known to one of skill in the art. For example, conditions for culturing and maintaining recombinant plant cells are described in Choi J.W., *et al.* (2001) *Adv Biochem Eng Biotechnol* 72:63-102; James E., Lee J.M. (2001) *Adv Biochem Eng Biotechnol* 72:127-56; Fischer R. and Emans N. (2000) *Transgenic Res.* 9(4-5):279-99; Fischer R., *et al.* (2000) *J Biol Regul Homeost*
- 10 *Agents* Apr-Jun;14(2):83-92; Kutchan T.M. (1996) *Gene* 1996 Nov 7;179(1):73-81; Creissen G., *et al.* (1996) *Biochem Soc Trans.* May;24(2):465-9; McKenna T.S., *et al.* (1996) *J Biotechnol* Jan 26;44(1-3):83-9; Ma J.K. and Hein M.B. (1995) *Plant Physiol* Oct;109(2):341-6; Taticek R.A., Lee C.W., Shuler M.L. (1994) *Curr Opin Biotechnol* Feb;5(2):165-74; Arathoon W.R., Birch J.R. (1986) *Science* Jun 13;232(4756):1390-5;
- 15 Murray K. (1980) *Philos Trans R Soc Lond B Biol Sci* Aug 11;290(1040):369-86.
- Furthermore, methods for culturing and maintaining the recombinant yeast organisms of the invention are also known to one of skill in the art, as described in, for example Kjeldsen T. (2000) *Appl Microbiol Biotechnol* Sep;54(3):277-86; Fischer R., *et al.* (1999) *Biotechnol Appl Biochem* Oct;30 (Pt 2):117-20; Mendoza-Vega O., Sabatie J,
- 20 Brown S.W. (1994) *FEMS Microbiol Rev* Dec;15(4):369-410; Moir D.T., Mao J.I. (1990) *Bioprocess Technol* 9:67-94.

- This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and
- 25 published patent applications cited throughout this application are incorporated herein by reference.

EXAMPLES

- 30 **EXAMPLE 1: Biological assay for B6 vitamers using *Saccharomyces uvarum*.**
- Quantitation of B6 vitamers in supernatants of cultures of micro-organisms or extracts of organisms that have been genetically modified to increase production of B6 vitamers is conveniently done using *Saccharomyces uvarum* (formerly and still often named *S. carlsbergensis*) strain ATCC 9080 as the indicator strain or test
- 35 organism. The method is essentially that described in the Difco Manual (1984, Difco Laboratories, Detroit, MI, 10th Edition, pp. 1104-1106), with the modification that 50 mg/liter of streptomycin sulfate is added to the liquid growth medium for the test

- 28 -

organism. However, any other appropriate indicator organism may be used, together with a medium that is appropriate for that organism that is free of B6 vitamers. For example, an *E. coli pdxB* mutant can be used in a standard minimal medium that is well known in the art, such as M9 glucose minimal medium (Miller, J., (1972) Experiments
5 in Molecular Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

When using *S. uvarum* strain ATCC 9080 as the indicator strain, Bacto Pyridoxine Y Medium (Difco Laboratories, available through VWR Scientific, Inc.), supplemented with 50 mg/liter streptomycin sulfate, is used for the serial dilutions, and PN, PL, or PM is used to generate the standard curve. The responses to these three
10 standard compounds are almost identical to each other with *S. uvarum* strain ATCC 9080 (Figure 3).

EXAMPLE 2: Deletion of a portion of the *yaaDE* operon in *B. subtilis*.

The *SOR* and *SNO* genes of *Cercospora nicotianae* were originally
15 identified by mutations that lead to hypersensitivity to singlet oxygen-generating reagents (Ehrenschaft, M., *et al.* (1999) *Proc. Natl. Acad. Sci. USA* 96: 9347-9378). Mutations in either of these genes also lead to PL auxotrophy. The protein sequences obtained from translation of the *SOR* and *SNO* open reading frames were used as
20 homology probes to search through the *B. subtilis* genome sequence using the BLAST homology search program of the Subtilist website. The *SOR* protein was significantly homologous to the YaaD protein, and the *SNO* protein was significantly homologous to the YaaE protein. Moreover, the genes encoding the YaaD and YaaE proteins (namely *yaaD* and *yaaE*) occur adjacent to each other on the *B. subtilis* chromosome as a two
gene operon.

25 General methods for growth, storage, transformation, and molecular biology of *B. subtilis* strains are given in Harwood, C., and Cutting, S. (1990), *Molecular Biological Methods for Bacillus*, John Wiley and Sons, New York, NY, hereby incorporated in its entirety by reference. The *yaaDE* operon DNA sequence was amplified using the Polymerase Chain Reaction (PCR) with Pfu Turbo DNA polymerase
30 (Stratagene, Inc., used according to the manufacturer's instructions). The DNA primers used were RY395 (SEQ ID NO:1) and RY396 (SEQ ID NO:2). RY395, the upstream primer, introduces an *XbaI* site and artificial ribosome binding site. RY396, the downstream primer, introduces a *BamHI* site. The template DNA was chromosomal DNA isolated from wild type *B. subtilis* strain PY79. The blunt ended PCR product was
35 ligated into the *EcoRV* site of pGEM5Zf(+) (Promega, Inc.) to give plasmid pAN368. Next, a gram positive chloramphenicol resistance gene on a blunt DNA fragment was ligated into pAN368 that had been cut with *HpaI*, to give plasmid pDX1F (SEQ ID

- 29 -

NO:5, Figure 4). pDX1F therefore is deleted for a portion of *yaaD* and a portion of *yaaE*. pDX1F was used to transform wild type *B. subtilis* strain PY79 to 5 mg/liter chloramphenicol resistance, and a double crossover event was confirmed using PCR and the same primers used to clone *yaaDE*. The resulting strain was named PX1.

- 5 PX1 was able to grow on Spizizen's minimal medium with trace elements (SMM) (Harwood, C., and Cutting, S. (1990) *Molecular Biological Methods for Bacillus*, John Wiley and Sons, New York, NY, pp. 548-549) supplemented with 2 μ M pyridoxal HCl (Sigma-Aldrich Chemical Co.), but it did not grow without the supplement. Thus it was established that at least one of *yaaD* or *yaaE* is required for
10 PLP synthesis in *B. subtilis*.

EXAMPLE 3: Deletion of *yhaF* in *B. subtilis*.

- The protein sequence of the *E. coli pdxF* gene was used as a probe to
15 search the *B. subtilis* genome as described in Example 1. The only significant homolog was *yhaF*. In a fashion similar to that of Example 1, the *yhaF* was cloned and deleted from the chromosome of PY79 using plasmid pDX11F (SEQ ID NO:6, Figure 5), to give strain PX11. The PCR primers used to clone *yhaF* were RY407 (SEQ ID NO:3) and RY408 (SEQ ID NO:4). The restriction sites used for insertion of the antibiotic
20 resistance gene were the *PshAI* and *EheI* sites in the *yhaF* coding region. PX11 is a serine auxotroph, but not a PL auxotroph. By comparison to *E. coli*, it appears that *yhaF* functions in serine synthesis and probably encodes the equivalent of *SerC*, but that the YhaF protein is not required for PLP synthesis in *B. subtilis*. Therefore, it is established that sequence homology alone does not necessarily imply functional homology.

25

EXAMPLE 4: Overexpression of the *yaaDE* operon in *B. subtilis*.

- The *XbaI* to *BamHI* fragment from pAN368 that contains the *yaaDE* operon and artificial ribosome binding site was inserted into either of two expression vectors, to yield plasmids pDX14R (SEQ ID NO:7) and pDX17R (SEQ ID NO:8),
30 respectively. In pDX14R and pDX17R, the *yaaDE* operon is expressed from the strong constitutive *B. subtilis* phage SP01 promoters, *P*₂₆ and *P*₁₅, respectively (see Figures 6 and 7).

- pDX14R and pDX17R were each transformed into wild type *B. subtilis* strain PY79, selecting for chloramphenicol resistance. The plasmids integrate into the
35 chromosome at the *yaaDE* locus by single crossover. The resulting strains were named PX14 and PX17, respectively.

- 30 -

PX14 and PX17 were grown for 48 hours at 37°C in 5 ml test tube cultures in a roller drum at about 100 rotations per minute. The culture medium was SVY (20 g Difco Veal Infusion Broth, 5 g Difco Yeast Extract, 2 g ammonium sulfate, 5 g sodium glutamate, and 30 g glucose per liter, buffered with 200 mM potassium phosphate, pH 7.0). Cells were removed by centrifugation followed by sterile filtration (Millipore 0.45 micron), and the supernatant solutions were assayed for PL equivalents using the biological assay described in Example 1. The parent strain, PY79 was grown and processed in similar fashion as a control. The uncultured SVY medium was assayed as another control, since it was likely that the SVY medium contained a measurable level of B6 vitamers. The results are shown in Table 2, below.

Table 2: Production of B6 vitamers by *Bacillus subtilis* derivatives in 48 hour test tube cultures grown in SVY

Strain	Cassette	Integration Target	OD ₆₀₀	Total B6 Vitamers ¹ mg/liter	Net B6 Vitamers ² mg/liter
PX14	<i>P₂₆yaaDE</i>	<i>yaaDE</i>	17	7.2	7.0
PX17	<i>P₁₅yaaDE</i>	<i>yaaDE</i>	17	4.9	4.7
PX1	<i>ΔyaaDE</i>	<i>yaaDE</i>	8	0.4	0.2
PY79	-	-	19	0.8	0.6
(Medium)	-	-	0.08	0.2	(0)

¹ Sum of PN, PL, PM, and derivatives thereof that can be utilized by pyridoxine indicator strain *S. carlbergensis* as a source of vitamin B6 for growth.

² Calculated by subtracting the amount assayed in the medium.

After subtracting the B6 vitamers contained in the medium, strain PX14 produced 7.0 mg/liter PL equivalents, while the parent PY79 produced only 0.6 mg/liter of PL equivalents. Thus, expression of the *yaaDE* operon has been shown to be rate limiting for B6 vitamer production in *B. subtilis*. Moreover, a genetically modified strain, where this rate limiting step was enhanced, produced more than a ten-fold increase in B6 vitamer secretion compared to that of the parent.

EXAMPLE 5: Shake flask experiments to determine B₆ vitamer production from *B. subtilis* strain PX14 containing an amplifiable P₂₆ *yaaDE* cassette.

To further test B₆ production, PX14 and PY79 were grown in parallel in shake flasks in soy flour, maltose, MOPS medium (SMM). The 200 ml baffled shake flasks contained 40 ml of medium, were covered with 4X

- 31 -

Bioshield covers, and shaken at 37°C and 300 rpm. Samples were taken at 24 and 48 hours and analyzed for vitamer concentration by HPLC (Table 3).

5 Titers produced by the parental control strain PY79 were 3 mg/l. PX14 produced a B₆ titer of 45 mg/L when grown in shake flasks containing SMM. In shake flasks, where the overall vitamer concentration increased with time, the amount of PN produced increased and exceeded that of PMP at 48 hours (Table 3).

B. subtilis has a fairly broad temperature range of growth up to approximately 50°C. A significant increase of B₆ titer was seen with *B. subtilis* strain PX14 when grown in shake flasks with SMM at 43°C as compared to 37°C (Table 4).
10 The B₆ titer increased more than 25% at 43°C as compared to that at 37°C.

TABLE 3. Vitamer composition of PX14 and PY79 grown in shake flasks in SMM³.

Strain	Time point (hr.)	PMP ¹	PM ¹	PL ¹	PN ¹	Total Vitamer ²
<u>PX14</u>	24	10.8	2.7	0.0	6.4	20
	48	15.5	8.5	1.7	19.0	45
PY79	24	1.0	0.0	0.0	0.0	1
	48	2.9	0.4	0.0	0.0	3

15 ¹ PMP, PM, PL and PM are reported in mg/l and quantified by HPLC.

² Total vitamer is equal to the sum of PMP, PM, PL and PM and reported in mg/l.

³ SMM contains in a final volume of 200 ml: 4.0 g soy flour, 1.6 g (NH₄)₂SO₄, 1.0 g monosodium glutamate, 2.0 ml 100 X PSTE trace minerals, 5.0 ml 4 M potassium phosphate buffer pH 7.2, 40 ml 1.5 M MOPS buffer pH 7.2, and deionized water.

20 Added after autoclaving at 20X concentrate to give a final concentration of 3% maltose with 5 mM magnesium chloride and 0.7 mM calcium chloride. 100 X PSTE contains 0.2 g/l MnCl₂·H₂O, .15 g/l ZnSO₄·7 H₂O, 0.2 g/l CoCl₂·6 H₂O, 0.025 CuSO₄·5 H₂O and 0.075 g/l Na₂MoO₄·2H₂O.

25 **TABLE 4. Vitamer composition of PX14 grown in shake flasks in SMM for 48 hours.**

Strain	Temperature (°C)	PMP ¹	PM ¹	PL ¹	PN ¹	Total Vitamer ²
<u>PX14</u>	37	15	9	2	19	45
	43	11	13	1	36	61

¹ PMP, PM, PL and PM are reported in mg/L and quantified by HPLC.

² Total vitamer is equal to the sum of PMP, PM, PL and PM and reported in mg/L.

5 **EXAMPLE 6: Complementation of *E. coli* *pdx* mutants by plasmids that express the *B. subtilis* *yaaDE* operon.**

Plasmid pDX14R, described above in Example 4, was used to transform various *E. coli* strains that contained mutations that lacked function in each of the known genes involved in PLP biosynthesis (except for *dxs*, which is an essential gene for *E.*
10 *coli*). The selection was for resistance to 250 mg/liter ampicillin. Each transformant was then tested for growth on minimal medium (SMM with 0.5 % glucose, see Example 2) supplemented with 100 mg/liter serine, and compared to growth of its respective untransformed parent on the same medium. All mutations tested were complemented by pDX14R. Specifically, *pdxA*, *pdxB*, *pdxF*, *pdxJ*, and *pdxH*, were all complemented by
15 pDX14R. Therefore, expression of the *B. subtilis* *yaaDE* operon in *E. coli* is sufficient for PLP biosynthesis, even in the absence of any one of the above functional *pdx* genes. Several important and unexpected conclusions or inferences can be drawn from these results. First, the substrate(s) for the enzyme(s) encoded by *yaaDE* must be present in *E. coli*, even when a biosynthetic intermediate normally used to make PLP is absent or
20 greatly reduced. Second, PNP or PLP is possibly the product of the enzyme(s) encoded by *yaaDE*. Third, since an early block in the *E. coli* PLP biosynthetic pathway (for example that in a *pdxB* mutant) does not prevent *yaaDE* from complementation, the substrates for the enzyme(s) encoded by *yaaDE* are not likely to be the same as for the last step in PMP or PLP synthesis in wild type *E. coli*. These unexpected results lead to
25 the possibility of producing B6 vitamers using *B. subtilis* *yaaDE* or the homologous genes from another organism (for example, but not limited to, *SOR* and *SNO* from *Cercospora nicotianae* or *PDX1* and *PDX2* from *S. cerevisiae*) in a heterologous host species, including, but not limited to, *E. coli* and *Oryza sativa*.

30 **EXAMPLE 7: Overexpression of the *yaaDE* operon in *E. coli*.**

Plasmids pDX14R and pDX17R were transformed into *E. coli* strain DH5 α (New England Biolabs), selecting for ampicillin resistance. The transformants were grown for 48 hours in 5 ml test tube cultures at 37°C, and the supernatants were worked up as in Example 3. The assay results for PL equivalents are shown in Table 5,
35 below.

- 33 -

Table 5: Production of B6 vitamers by *Escherichia coli* harboring plasmids containing engineered *Bacillus subtilis* genes¹

Strain	Plasmid Cassette	OD ₆₀₀	Total B6 Vitamers ² mg/liter	Net B6 Vitamers ³ mg/liter
DH5α	<i>P₂₆yaaDE</i>	7.6	3.2	3.1
DH5α	<i>P₁₅yaaDE</i>	8.2	3.2	3.1
DH5α	-	9	0.1	(0)

¹*E. coli* test tube cultures are grown in SVY for 48 hours.²Sum of PN, PL, PM, and derivatives thereof that can be utilized by pyridoxine indicator strain *S. carlbergensis* as a source of vitamin B6 for growth.³Calculated by subtracting the amount assayed in DH5α not containing plasmid.

Thus it has been shown that the *yaaD* and *yaaE* genes can be expressed in a heterologous host strain, and B6 vitamers can still be overproduced. By extension of this approach, the *yaaD* and *yaaE* genes of *B. subtilis* can be overexpressed in any organism where an overexpression system exists, and in the resulting strains, B6 vitamers will be overproduced. Overproduction of the rate limiting enzyme for B6 vitamer production in any organism that is capable of producing B6 vitamers will lead to overproduction of B6 vitamers.

EXAMPLE 8: Test tube experiment to determine B₆ vitamer production from *E. coli* strain DH5α (pDX14) grown on SVY supplemented with pentose or hexose carbon sources.

In order to test whether feeding pentoses could enhance B₆ synthesis, *E. coli* strain DH5α harboring a plasmid containing the *P₂₆yaaDE* cassette were grown in a variety of SVY based media containing a pentose (xylose or ribose) or hexose (glucose or maltose) as the carbohydrate source. The strains were also grown on SVY medium containing no carbohydrate source as a control. Production of B₆ vitamers from *E. coli* strain DH5α(pDX14) grown in SVY ribose is greater than that from *E. coli* strain DH5α(pDX14) grown in SVY xylose, glucose, arabinose or maltose. More than 60 mg/l of total B₆ vitamers have been produced in the DH5α(pDX14) cultures grown in SVY ribose test tube with PN as the major product (Table 6).

TABLE 6. Production of B₆ vitamers by *E. coli* harboring a plasmid containing engineered *B. subtilis* genes and grown in the presence or absence of hexose or pentose carbon sources.

Strain	Sugar	OD ₆₀₀	Total Vitamer ¹
DH5α(pDX14)	Glucose	9	8
	Ribose	16	61
	Xylose	8	31
	Arabinose	7	21
	None	7	25
DH5α	Glucose	9	4
	Ribose	18	5
	Xylose	9	4
	Arabinose	9	1
	None	7	3

¹Total vitamer concentration (mg/l) is quantified by HPLC and equal to the sum of PMP, PM, PL, and PN.

EXAMPLE 9: Vitamin B₆ titers of a *pdxB* *E. coli* strain producing YaaD in the absence of YaaE

In order to determine the titers of B₆ produced from YaaD alone, in the absence of YaaE, *E. coli* strain WG1012 (*pdxB*) was transformed with pDX14 and pDX24 (plasmid isolates N2, D2 and D6), and control plasmid pBR322. These transformed strains were grown in 5 mL test tube cultures in SVY ribose in roller drums at 37°C for 48 hours. Ribose was chosen as the carbon source, since past experiments showed that ribose improved B₆ vitamer production in *E. coli* transformants. B₆ titers of culture supernatants were determined by HPLC assay. In all cases, the plasmids that complemented the *pdxB* strain led to measurable production of B₆, whereas as the plasmids (*i.e.* pBR322) that did not complement did not lead to any measurable B₆ (Tables 7 and 8). Several isolates of pDX24, which contains the *yaaD* ORF, produced approximately 7-10 mg/L of the B₆ vitamers. However, *E. coli* strain WG1012 (*pdxB*) containing pDX24 produced only a fraction of the amount of B₆ as compared to the *E. coli* strain WG1012 harboring pDX14 containing the *P₂₆yaaDE* cassette (Table 8).

Apparently, YaaD is functional by itself and can catalyze the synthesis of vitamers similar in composition to those synthesized by YaaDE, albeit less efficiently. It appears that while YaaE is not absolutely essential for B₆ synthesis, it provides a supportive role to YaaD, thereby leading to higher B₆ titers. YaaD is also able

- 35 -

to function independently of YaaE in *B. subtilis*, however, less efficiently than when YaaE is present. Expressing a copy of *P₂₆ yaaD* in either PX1 or PY79 resulted in higher titers of B₆ vitamers as compared to the respective parental controls.

5 **TABLE 7. *YaaD* complements a *pdxB* *E. coli* auxotroph.**

Strain and plasmid	Cassette	PIX free	PIX free + 2 μ M PL
<i>E. coli pdxB</i>			
pBR322	None	-	+
pDX14	<i>P₂₆yaaDE</i>	+	+
pDX24	<i>P₂₆yaaD</i>	+	+

10 **TABLE 8. Vitamer profile of *E. coli pdxB* strains harboring a plasmid containing a *P₂₆yaaDE* or a *P₂₆yaaD* cassette.**

Plasmid	Isolate	Cassette	OD ₆₀₀	PM	PL	PN	PM +PL +PI (mg/L)
pDX14		<i>P₂₆yaaDE</i>	14.1	0.6	0.0	28.8	29.4
pDX24	N2	<i>P₂₆yaaD</i>	12.2	0.0	2.0	7.4	9.4
	D2	<i>P₂₆yaaD</i>	15.5	0.0	0.0	6.9	6.9
	D6	<i>P₂₆yaaD</i>	13.6	0.0	0.0	9.7	9.7
pBR322		-	12.4	0.0	0.0	0.0	0.0
SVY-ribose			-	0.0	0.0	0.0	0.0

5 mL test tube cultures were grown in SVY-ribose and roller drums at approximately 100 RPM, 37°C for 48 hours. Vitamers were quantified by HPLC.

The YaaD and YaaE protein sequences were used as probes to search the
 15 NCBI database for homologs in plants using the BLAST™ program which can be found
 at the National Center for Biotechnology Information website (Altschul S.F (1990)
J. Mol. Biol. 215(3):403-10). Several homologs of YaaD were found in several genera
 of plants, including *Arabidopsis*, *Oryza*, *Ginkgo*, *Hevea*, *Phaseolus*, and *Stellaria*. Two
 homologs of YaaE were found in *Arabidopsis thaliana*. However, no homologs of *pdxA*
 20 and *pdxJ* were found. Therefore, the plant kingdom appears to use the Type B Pathway
 for B₆ vitamer biosynthesis. Thus for example, overexpression of the YaaD homolog
 (GenBank accession number AAL73561) from *Oryza sativa* (rice), and the *A. thaliana*
 homolog of YaaE (GenBank accession number AB011483) together in a plant using
 methods well known in the art, such as expression from the Cauliflower Mosaic Virus
 25 35S promoter, will lead to overproduction of B₆ vitamers in that plant.

EXAMPLE 10: Other routes to increasing the activity of enzymes involved in B6 vitamer synthesis.

The overexpression of the *yaaDE* operon leads to an increase in the amount of the encoded enzyme(s), which in turn leads to an increase in the total activity of said enzyme(s). Increase in this activity leads to an increase in the production B6 vitamer. Other methods can be used to increase the activity of the relevant enzyme(s) under conditions of B6 vitamer production. For example, in addition to increasing the amount of a relevant enzyme(s), the total activity of the relevant enzyme(s) can be increased by mutating the gene(s) to increase the specific activity of the enzyme(s), and/or by mutating the gene(s) to encode a feedback resistant variant of the enzyme(s). Such desirable mutations can be obtained by screening large numbers of mutants for the increased activity as evidenced by an increase in B6 vitamer production as described in Example 4, or by selecting for mutants that are resistant to inhibitors that are specific for the PLP biosynthetic pathway, and screening among those mutants for an increase in B6 vitamer production. Examples of such inhibitors are isoniazid, iproniazid, and ginkgotoxin (4'-methoxy pyridoxine) (Dempsey and Arcement (1971) J. Bacteriol. 107(2): 580-582; Pflug, W., and Lingens, F., (1978) Hoppe-Seyler's Z. Physiol. Chem. 359: 559-570; Fiehe, K., et al., (2000) J. Nat. Prod. 63(2): 185-189).

EXAMPLE 11: Processing of biosynthetic B6 vitamers.

A B6 vitamer produced by a genetically modified organism of the invention can be harvested and processed into a format that is appropriate for commercial use. For example, after culturing a B6 vitamer producing micro-organism in liquid culture, the entire culture, including cells can be dried by evaporation or by spray drying, and the resulting powder can be mixed into animal feeds. Alternatively, the cells can be first removed by centrifugation or filtration, and the resulting supernatant solution can be dried as described above. As another alternative, the B6 vitamer can be purified from the culture broth by techniques well known in the art, such as filtration, reverse osmosis, column chromatography (ion exchange, hydrophobic or hydrophilic adsorption, gel filtration, etc.), solvent extraction, precipitation, distillation, evaporation, and the like. If the B6 vitamer producing organism is a plant, then the appropriate portion of the plant (for example the leaves, stems, roots, flowers, fruits, seeds, or any combination thereof) can be harvested and processed. For example the plant material can be dried and used directly, or the material can be pulverized or ground and the B6 vitamer extracted and/or processed as described above for cultures.

- 37 -

The production organism can be a micro-organism that normally inhabits the gut of humans or an animal if interest (for example one of many bacteria of the genus *Lactobacillus*, such as *L. acidophilus*), and the B6 vitamer can be delivered by ingestion of the organism.

5

EXAMPLE 12: Genes homologous to *yaaDE* expressed in host organisms for the production of B6.

Preferred methods for the production of vitamin B6 involve expression of *Bacillus subtilis yaaD* and/or *yaaE* or expression of genes that are homologous to *Bacillus subtilis yaaD* and/or *yaaE* in host organisms (type A or type B organisms) such as *E. coli*, *S. cerevisiae*, *Arabidopsis thaliana*, etc. In order to identify genes or proteins that are homologous to *yaaD* and *yaaE* a procedure such as a protein or nucleotide BLAST™ (Basic Alignment Search Tool) search can be implemented (Altschul, Stephen F., et al. (1997) *Nucleic Acids Res.* 25:3389-3402). The BLAST™ search tool and can be found and used at the National Center for Biotechnology Information website. BLAST™ is an algorithm designed to compare sequences and provide sequence alignments between two or more previously characterized sequences and also provides a method for rapid searching of nucleotide and protein databases. A typical description line of a BLAST output table is given as

“gi|586857|sp|P37527|YAAD_BACSU 31.5 kDa guanylated protei... 506 e-142” where “gi” is the GenBank identifier of the subject which in this case is number “586857”, “sp” represents the databank from which the subject was retrieved, “P37527” represents the GenBank accession number and “YAAD_BACSU 31.5 kDa guanylated protei...” is a brief description of the sequence, the number “506” represents the bit score of the highest-scoring HSP’s (high scoring pairs) and “e-142” is the E value that represents the statistical significance of a given alignment. The E value also reflects the size of the database and the scoring value used. The lower the E value, the more significant the homology. The description lines in the BLAST™ output table (Table 9, below) represents a typical BLAST™ query of the primary amino acid sequence of *B. subtilis* YaaD and is sorted by increasing E value with the most significant alignments (lowest E values) at the top. A similar BLAST™ query of primary amino acid sequence of *B. subtilis* YaaE is represented in Table 10, below. These alignments represent a small portion of the protein sequences homologous to YaaD and YaaE protein sequences from various organisms as the sequences from many organisms have not been, or only partially, categorized into the current databases.

Table 9: Sequences producing significant alignments to *Bacillus subtilis* YaaD

					Score	E
					(bits)	Value
	gi	586857	sp P37527 YAAD_BACSU	31.5 kDa guanylylated protei...	506	e-142
5	gi	21397980	ref NP_653965.1	SOR_SNZ, SOR/SNZ family [Bacil...	453	e-126
	gi	10172634	dbj BAB03741.1	superoxide-inducible protein [B...	437	e-122
	gi	15603097	ref NP_246169.1	unknown [Pasteurella multocida...	435	e-121
	gi	16414718	emb CAC97434.1	similar to a protein required f...	431	e-120
	gi	22778374	dbj BAC14643.1	superoxide-inducible protein 7(...	430	e-119
10	gi	16411571	emb CAD00179.1	similar to a protein required f...	428	e-119
	gi	25364956	pir H89818	conserved hypothetical protein SA04...	424	e-118
	gi	22090614	dbj BAC06852.1	superoxide-inducible protein [B...	418	e-116
	gi	23038401	gb ZP_00070557.1	hypothetical protein [Oenococ...	392	e-108
	gi	7482301	pir F69188	ethylene-inducible protein - Methano...	360	1e-98
15	gi	22970419	gb ZP_00017505.1	hypothetical protein [Chlorof...	359	3e-98
	gi	6459121	gb AAF10938.1 AE001982_12	singlet oxygen resista...	346	2e-94
	gi	13310484	gb AAK18310.1 AF344827_1	Sor-like protein [Gink...	342	5e-93
	gi	23017679	gb ZP_00057403.1	hypothetical protein [Thermob...	340	1e-92
	gi	18481963	gb AAL73561.1 AC079632_5	Putative ethylene-indu...	339	2e-92
20	gi	11358736	pir T48163	pyridoxine biosynthesis protein-lik...	338	4e-92
	gi	3123099	sp O14027 YEM4_SCHPO	Hypothetical protein C29B12...	338	7e-92
	gi	11359355	pir T46647	pyridoxine biosynthesis protein pyr...	338	8e-92
	gi	2129913	pir S60047	ethylene-responsive protein 1 - Para...	337	1e-91
	gi	10719739	gb AAG17942.1	putative pyridoxine biosynthetic...	337	2e-91
25	gi	11362638	pir T46646	pyridoxine biosynthesis protein pdx...	336	2e-91
	gi	20094807	ref NP_614654.1	Pyridoxine biosynthesis enzyme...	336	3e-91
	gi	7462114	pir A72372	conserved hypothetical protein - The...	335	4e-91
	gi	21617922	gb AAM66972.1	pyridoxine biosynthesis protein-...	335	5e-91
	gi	2193896	emb CAB09637.1	hypothetical protein MLCL581.12c...	333	1e-90
30	gi	20807305	ref NP_622476.1	Pyridoxine biosynthesis enzyme...	333	2e-90
	gi	15827141	ref NP_301404.1	putative pyridoxine biosynthes...	332	3e-90
	gi	13878067	gb AAK44111.1 AF370296_1	putative SOR1 from the...	332	3e-90
	gi	21220023	ref NP_625802.1	conserved hypothetical protein...	330	1e-89
	gi	18076239	emb CAC81977.1	err-related and stress induced ...	330	2e-89
35	gi	20090425	ref NP_616500.1	pyridoxine biosynthesis protei...	328	4e-89
	gi	6137073	emb CAB59635.1	ethylene responsive receptor, ER...	328	5e-89
	gi	23052101	gb ZP_00078783.1	hypothetical protein [Methano...	327	9e-89
	gi	3123042	sp O06208 YQ06_MYCTU	Hypothetical protein Rv2606...	327	2e-88
	gi	15842146	ref NP_337183.1	pyridoxine biosynthesis protei...	327	2e-88
40	gi	25364954	pir A96973	probable phosphate-utilizing enzyme...	323	2e-87
	gi	23335752	gb ZP_00120985.1	hypothetical protein [Bifidob...	322	4e-87
	gi	21323554	dbj BAB98181.1	Pyridoxine biosynthesis enzyme ...	322	5e-87
	gi	19552014	ref NP_600016.1	pyridoxine biosynthesis enzyme...	322	5e-87
	gi	23465712	ref NP_696315.1	widely conserved protein in up...	320	1e-86
45	gi	21228534	ref NP_634456.1	putative pyridoxine biosynthes...	318	5e-86
	gi	2501580	sp Q58090 Y677_METJA	Hypothetical protein MJ0677...	317	1e-85
	gi	23493620	dbj BAC18589.1	conserved hypothetical protein ...	314	1e-84
	gi	13541829	ref NP_111517.1	Predicted phosphate-utilizing ...	313	2e-84
	gi	18893665	gb AAL81653.1	ethylene-inducible protein homol...	312	4e-84
50	gi	14591161	ref NP_143237.1	ethylene-responsive protein [P...	311	6e-84
	gi	14521000	ref NP_126475.1	ETHYLENE-RESPONSIVE PROTEIN [P...	311	7e-84
	gi	15622519	dbj BAB66510.1	336aa long hypothetical stress-...	308	4e-83
	gi	6015903	emb CAB57730.1	hypothetical protein [Sulfolobus...	307	1e-82
	gi	10639689	emb CAC11661.1	probable pyridoxine biosynthesi...	304	1e-81
55	gi	1078513	pir S55082	hypothetical protein YMR096w - yeast...	303	2e-81
	gi	14972957	gb AAK75562.1	pyridoxine biosynthesis protein ...	302	5e-81
	gi	7483295	pir D69313	ethylene-inducible protein homolog ...	301	7e-81
	gi	15458966	gb AAL00126.1	Pyridoxine biosynthesis protein ...	301	9e-81
	gi	19704795	ref NP_604357.1	pyridoxine biosynthesis protei...	299	4e-80

- 39 -

	gi 1074877 pir F64173	hypothetical protein HI1647 - Haemop...	298	5e-80
	gi 12802367 gb AAK07850.1 AF309689_12	Snz-type pyridoxine v...	297	1e-79
	gi 3172534 gb AAC18606.1	hypothetical protein IP1 [Francis...	294	1e-78
	gi 22405887 gb ZP_00000750.1	hypothetical protein [Ferrop1...	293	2e-78
5	gi 1730655 sp P53824 SNZ2_YEAST SNZ2 PROTEIN >gi 6323996 re...		293	2e-78
	gi 1084717 pir S56196	hypothetical protein YFL059w - yeast...	292	3e-78
	gi 25364947 pir A84331	hypothetical protein Vng1793c [impo...	288	9e-77
	gi 23479541 gb EAA16340.1	ethylene-inducible protein hever...	288	9e-77
	gi 23612291 ref NP_703871.1	pyridoxine biosynthetic enzyme...	287	1e-76
10	gi 14600562 ref NP_147079.1	ethylene-responsive protein 1 ...	285	5e-76
	gi 18313608 ref NP_560275.1	stress induced protein, conjec...	279	4e-74
	gi 4103954 gb AAD01898.1	A37 [Arabidopsis thaliana] >gi 41...	249	2e-65
	gi 2501581 sp Q50841 YTR5_METVA	Hypothetical protein in tRN...	237	1e-61
	gi 44737 emb CAA25434.1	unidentified reading frame [Methan...	218	6e-56
15	gi 2501579 sp Q41348 H47_STELP HYPOTHETICAL PROTEIN H47		207	1e-52
	gi 7488891 pir S71492	ethylene-responsive protein 2 - Para...	205	5e-52
	gi 297176 emb CAA50602.1	expressed ORF [Stellaria longipes...	196	4e-49
	gi 21671884 gb AAM74246.1 AC074355_8	Putative protein simil...	100	2e-20
	gi 20521394 dbj BAB91905.1	putative ethylene-responsive pro...	90	4e-17
20	gi 22138453 gb AAM93437.1	putative ethylene-inducible prot...	84	3e-15
	gi 3335369 gb AAC27170.1	similar to SOR1 from the fungus C...	78	1e-13
	gi 15217264 gb AAK92608.1 AC078944_19	Hypothetical protein ...	57	2e-07

25 **Table 10: Sequences producing significant alignments to *Bacillus subtilis* YaaE**

			Score	E
			(bits)	Value
	gi 467402 dbj BAA05248.1	unknown [Bacillus subtilis] >gi 2...	382	e-105
	gi 21397981 ref NP_653966.1	SNO, SNO glutamine amidotransf...	258	3e-68
30	gi 10172635 dbj BAB03742.1	amidotransferase [Bacillus halo...	231	4e-60
	gi 22090615 dbj BAC06853.1	2-deoxy-scylo-inosose synthase...	221	4e-57
	gi 23038400 gb ZP_00070556.1	hypothetical protein [Oenococ...	216	1e-55
	gi 14246288 dbj BAB56682.1	conserved hypothetical protein ...	206	1e-52
	gi 16414719 emb CAC97435.1	lin2206 [Listeria innocua] >gi ...	190	1e-47
35	gi 15603098 ref NP_246170.1	unknown [Pasteurella multocida...	190	1e-47
	gi 22778373 dbj BAC14642.1	amidotransferase [Oceanobacillu...	187	5e-47
	gi 15643238 ref NP_228282.1	amidotransferase, putative [Th...	187	6e-47
	gi 16411572 emb CAD00180.1	lmo2102 [Listeria monocytogenes...	184	6e-46
	gi 21220022 ref NP_625801.1	conserved hypothetical protein...	176	1e-43
40	gi 2145628 pir S72721	amidotransferase hisH homolog - Myco...	176	2e-43
	gi 7447522 pir C70570	hypothetical protein Rv2604c - Mycob...	176	2e-43
	gi 13092704 emb CAC29982.1	conserved hypothetical protein ...	176	2e-43
	gi 18977900 ref NP_579257.1	imidazoleglycerol-phosphate sy...	174	7e-43
	gi 6459120 gb AAF10937.1 AE001982_11	amidotransferase HisH,...	172	2e-42
45	gi 23017678 gb ZP_00057402.1	hypothetical protein [Thermob...	172	3e-42
	gi 7447524 pir D71007	hypothetical protein PH1354 - Pyroco...	162	2e-39
	gi 9757756 dbj BAB08237.1	amidotransferase hisH-like prote...	162	2e-39
	gi 14521001 ref NP_126476.1	imidazoleglycerol-phosphate sy...	160	6e-39
	gi 21228535 ref NP_634457.1	Imidazoleglycerol-phosphate sy...	160	7e-39
50	gi 23052100 gb ZP_00078782.1	hypothetical protein [Methano...	160	8e-39
	gi 25314121 pir H95170	conserved hypothetical protein SP14...	157	8e-38
	gi 19915437 gb AAM04979.1	pyridoxine biosynthesis protein ...	156	1e-37
	gi 15458965 gb AAL00125.1	Conserved hypothetical protein [...]	156	2e-37
	gi 18424366 ref NP_568922.1	imidazoleglycerol-phosphate sy...	155	2e-37
55	gi 23465711 ref NP_696314.1	conserved hypothetical protein...	152	3e-36
	gi 23335751 gb ZP_00120984.1	hypothetical protein [Bifidob...	151	5e-36
	gi 13540888 ref NP_110576.1	Predicted glutamine amidotrans...	149	2e-35
	gi 21323555 dbj BAB98182.1	Predicted glutamine amidotransf...	145	4e-34
	gi 2650108 gb AAB90721.1	imidazoleglycerol-phosphate synth...	144	8e-34

- 40 -

	gi	20515816	gb	AAM24079.1	predicted glutamine amidotransfe...	143	2e-33
	gi	16081194	ref	NP_393487.1	hypothetical protein [Thermopl...	142	2e-33
	gi	2128068	pir	C64507	hypothetical protein homolog MJ1661 ...	142	3e-33
	gi	5103636	dbj	BAA79157.1	186aa long hypothetical protein ...	139	2e-32
5	gi	25314111	pir	C84409	imidazoleglycerol-phosphate synthas...	139	3e-32
	gi	15023464	gb	AAK78573.1	AE007574_11 Glutamine amidotransp...	139	3e-32
	gi	20094498	ref	NP_614345.1	Predicted glutamine amidotrans...	138	3e-32
	gi	7447523	pir	F69120	conserved hypothetical protein MTH19...	132	3e-30
	gi	1574496	gb	AAC23295.1	conserved hypothetical protein [H...	131	4e-30
10	gi	19114059	ref	NP_593147.1	conserved hypothetical protein...	127	7e-29
	gi	12802368	gb	AAK07851.1	AF309689_13 Sno-type pyridoxine v...	124	7e-28
	gi	9954418	gb	AAG09049.1	AF294268_1 pyridoxine synthesis pr...	124	9e-28
	gi	18076241	emb	CAC81978.1	SNO protein [Suberites domuncula]	124	1e-27
	gi	18076243	emb	CAC81976.1	SNO protein [Suberites domuncula]	122	2e-27
15	gi	25314108	pir	H90203	glutamine amidotransferase, probabl...	120	9e-27
	gi	22970420	gb	ZP_00017506.1	hypothetical protein [Chlorof...	120	1e-26
	gi	22405886	gb	ZP_00000749.1	hypothetical protein [Ferrop...	117	8e-26
	gi	13937025	gb	AAK50016.1	AF363613_1 pyridoxine [Aspergillu...	114	6e-25
	gi	18313609	ref	NP_560276.1	conserved hypothetical protein...	112	3e-24
20	gi	15921733	ref	NP_377402.1	200aa long conserved hypotheti...	111	6e-24
	gi	1302459	emb	CAA96268.1	ORF YNL334c [Saccharomyces cerev...	103	1e-21
	gi	1084718	pir	S56195	probable membrane protein YFL060c - ...	103	2e-21
	gi	1078512	pir	S55081	hypothetical protein YMR095c - yeast...	102	4e-21
	gi	23112427	gb	ZP_00097910.1	hypothetical protein [Desulfi...	101	7e-21
25	gi	23489463	gb	EAA21585.1	Glutamine amidotranspherase [Pla...	85	6e-16
	gi	21228132	ref	NP_634054.1	Amidotransferase hisH [Methano...	51	8e-06
	gi	20089791	ref	NP_615866.1	imidazoleglycerol-phosphate sy...	50	1e-05
	gi	23023420	gb	ZP_00062656.1	hypothetical protein [Leucono...	50	2e-05
	gi	23025661	gb	ZP_00064612.1	hypothetical protein [Leucono...	50	2e-05
30	gi	22999839	gb	ZP_00043799.1	hypothetical protein [Magnet...	49	4e-05
	gi	12229838	sp	Q9P4P9	HIS5_EMENI Imidazole glycerol phosph...	49	6e-05
	gi	23129284	gb	ZP_00111116.1	hypothetical protein [Nostoc ...	48	8e-05
	gi	25287041	pir	AE1977	amidotransferase [imported] - Nosto...	48	9e-05
	gi	22776228	dbj	BAC12505.1	amidotransferase [Oceanobacillu...	47	1e-04
35	gi	22776424	dbj	BAC12700.1	phosphoribosylformylglycinamidi...	47	2e-04
	gi	14916682	sp	Q9UXW5	PURQ_PYRAB Phosphoribosylformylglycin...	46	2e-04
	gi	11258455	pir	H81274	amidotransferase Cj1315c [imported]...	46	2e-04
	gi	23109765	gb	ZP_00095937.1	hypothetical protein [Novosph...	46	3e-04
	gi	12229843	sp	Q9RDX3	HIS5_LEGPN Imidazole glycerol phosph...	45	4e-04
40	gi	23112136	gb	ZP_00097663.1	hypothetical protein [Desulfi...	45	6e-04
	gi	15559183	gb	AAK58487.1	unknown [Campylobacter jejuni]	45	6e-04

EXAMPLE 13: Characterizing functional *B. subtilis yaaD* and *yaaE* homologs
 45 by complementation of *E. coli pdx* mutants by plasmids that express the *B. subtilis yaaD* and/or *yaaE* homologs.

In order that any given *B. subtilis yaaD* and/or *yaaE* homolog has similar function as the *B. subtilis* genes, the method of rescuing *E. coli* or other *pdx* auxotrophs can be employed. Briefly, DNA homologous to *yaaD* and *yaaE* sequences or DNA
 50 encoding proteins homologous to YaaD and/or YaaE, identified by BLAST™ or other methods, can be amplified using the Polymerase Chain Reaction (PCR) with Pfu Turbo DNA polymerase (Stratagene Inc., used according to the manufacturers instructions) using appropriately designed DNA primers. In an analogous method to the

overexpression of the *yaaDE* operon in *B. subtilis* described in Example 4, a DNA fragment that contains a homologous gene or operon (Type B pathway) and artificial ribosome binding site can be inserted into an appropriate expression vector for example either of two expression vectors from Example 4. In these plasmids the *yaaDE* homologs would be expressed from a strong constitutive *B. subtilis* phage SP01 promoter such as P_{15} or P_{26} . The resulting plasmids can be used to transform various *E. coli* or *B. subtilis* strains that contain mutations that lack function in known genes involved in PLP synthesis. The transformants can be selected for resistance to an appropriate antibiotic (such as ampicillin) that is encoded by the plasmid harboring the *yaaDE* homologs. Transformants can be tested for growth on minimal medium (SMM with 0.5% glucose) supplemented with 100 mg/L serine, and compared to growth of its respective untransformed parent on the same medium. True transformants (as opposed to revertants) that grow on minimal medium without any added B6 vitamers, can be concluded to contain a gene or genes that function in the biosynthesis of B6.

EXAMPLE 14: Assay for the detection of B6 vitamers.

An assay for the detection of B6 vitamers produced in heterologous systems can be performed by using *Saccharomyces uvarum* as an indicator strain described in Example 1. An alternative assay is an HPLC assay. Quantitation of B6 vitamers in supernatants of cultures of microorganisms or extracts of organisms that have been genetically modified to increase the production of B6 vitamers can be accomplished by filtration (Centricon, 0.45 μ m), followed by high pressure liquid chromatography (HPLC). Quantitation is accomplished by comparing samples to standard curves generated by running a known solution of PMP, PLP, PNP, PM, PL or PN. For the HPLC assay, filtered supernatants are diluted 1/5 with 0.45 μ m filtered Buffer A (50mM KPO₄, 5 mM EDTA, 2% acetonitrile, pH 7.0) and 10 μ L of this solution is injected onto a 250 x 4.6 mm Aqua™ 5 μ C18 column run on an Agilent™ 1100 series HPLC equipped with a G1321A fluorescence detector. The excitation wavelength is 330 nM and the emission wavelength is 380 nM. An isocratic flow is maintained on the C18 column for 15 minutes with buffer A at 1 mL/min. This is followed by a 2 minute and a 15 minute 2 % and 95% acetonitrile (in water without salts) wash, respectively. An equilibration step consisting of a 2% ACN wash for 5 min followed by a 5 minute Buffer A wash is performed in preparation for the next sample injection. Typical retention times for PMP, PM, PLP, PL and PN are 2.7, 4.6, 5.3, 7.8 and 9.6 minutes, respectively. Chem Station™, the accompanying software package provided by Agilent, is utilized for instrument control, data acquisition and data

- 42 -

evaluation and run on a HP Pentium™ 4 computer that supports Microsoft™ Windows NT 4.0 updated with a Microsoft™ Service Pack (SP6a).

EXAMPLE 15: Genes homologous to the type A B6 biosynthetic pathway

5 expressed in host organisms for the production of B6.

Preferred methods for the production of vitamin B6 feature the expression of a gene of the type A pathway, *e.g.*, *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH* or *dxs* homologs, or a combination thereof, in host organisms (type A or type B organisms) such as *E. coli*, *S. cerevisiae*, *Arabidopsis thaliana*, etc. In order to identify genes or
10 proteins that are homologous to the type A pathway, a procedure such as a protein or nucleotide BLAST™ search can be implemented as described in Example 12 (Altschul, Stephen F. (1997) *Nucleic Acids Res.* 25:3389-3402). Function can further be confirmed as described in Example 13.

15 Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

What is claimed:

1. A method for producing a B6 vitamer comprising culturing an organism with an increased YaaD and/or YaaE activity as compared to the parent
5 organism.
2. The method of claim 1, wherein increased YaaD and/or YaaE activity is due to increased expression of a nucleic acid molecule encoding a YaaD polypeptide and/or a YaaE polypeptide as compared to an unmodified parent organism.
10
3. The method of claim 2, wherein increased *yaaD* and/or *yaaE* nucleic acid molecule expression is due to the deregulation or introduction of nucleic acid molecules encoding a YaaD polypeptide and/or a YaaE polypeptide into the organism.
15
4. The method of claim 3, wherein said *yaaD* nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:21 and/or wherein said *yaaE* nucleic acid encodes a polypeptide comprising the amino acid sequence SEQ ID NO:23.
20
5. The method of claim 3, wherein said *yaaD* nucleic acid encodes a polypeptide comprising an amino acid sequence which is at least 30% identical to the amino acid sequence of SEQ ID NO:21, said polypeptide having a YaaD activity.
- 25 6. The method of claim 3, wherein said *yaaE* nucleic acid encodes a polypeptide comprising an amino acid sequence which is at least 30% identical to the amino acid sequence of SEQ ID NO:23, said polypeptide having a YaaE activity.
7. The method of claim 3, wherein a nucleic acid molecule
30 comprising the nucleotide sequence of SEQ ID NO:20 and/or SEQ ID NO:22 is introduced.
8. The method of claim 1, wherein the organism is selected from the group consisting of plants and microorganisms.
- 35 9. The method of claim 8, wherein the microorganism is selected from the group consisting of algae, fungi, yeast, and bacteria.

10. A method for producing a B6 vitamer comprising culturing an organism with an increased *Epd*, *PdxA*, *PdxJ*, *PdxF*, *PdxB*, *PdxH*, and/or a *Dxs* activity as compared to the parent organism.

5 11. The method of claim 10, wherein increased *Epd*, *PdxA*, *PdxJ*, *PdxF*, *PdxB*, *PdxH*, and/or a *Dxs* activity is due to increased expression of a nucleic acid molecule encoding an *Epd*, *PdxA*, *PdxJ*, *PdxF*, *PdxB*, *PdxH*, and/or *Dxs* polypeptide as compared to an unmodified parent organism.

10 12. The method of claim 11, wherein increased *epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH*, and/or *dxs* nucleic acid molecule expression is due to the introduction of nucleic acid molecules encoding an *Epd*, *PdxA*, *PdxJ*, *PdxF*, *PdxB*, *PdxH*, and/or *Dxs* polypeptide into the organism.

15 13. The method of claim 12, wherein said *pdxA* nucleic acid encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:25 and/or wherein said *pdxJ* nucleic acid encodes a polypeptide comprising the amino acid sequence SEQ ID NO:27.

20 14. The method of claim 12, wherein said *pdxA* nucleic acid encodes a polypeptide comprising an amino acid sequence which is at least 30% identical to the amino acid sequence of SEQ ID NO:25, said polypeptide having a *PdxA* activity.

25 15. The method of claim 12, wherein said *pdxJ* nucleic acid encodes a polypeptide comprising an amino acid sequence which is at least 30% identical to the amino acid sequence of SEQ ID NO:27, said polypeptide having a *PdxJ* activity.

30 16. The method of claim 12, wherein a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:24 and/or SEQ ID NO:26 is introduced.

17. The method of claim 10, wherein the organism is selected from the group consisting of plants and microorganisms.

35 18. The method of claim 17, wherein the microorganism is selected from the group consisting of algae, fungi, yeast, and bacteria.

19. An organism that has been genetically modified to comprise a recombinant DNA molecule that results in the increase of the activity of one or more enzymes that catalyze(s) a step in the biosynthesis of a B6 vitamer, such that B6 vitamer
5 production from said modified organism is increased compared to B6 production in an unmodified parent organism.

20. The organism of claim 19, wherein B6 vitamer production is at least ten-fold higher than from the unmodified parent organism.
10

21. The organism of claim 19, wherein said enzyme is one or more of YaaD or YaaE, or a homologue thereof, wherein said homologue has the ability to rescue an auxotroph in a test system.

22. The organism of claim 21, wherein said homologue is selected from the homologues listed in Table 9 or Table 10.
15

23. The organism of claim 19, wherein said organism is genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step
20 in the biosynthesis of a B6 vitamer.

24. The organism of claim 23, wherein said genes are derived from *Bacillus*.

25. The organism of claim 23, wherein said genes are derived from *Bacillus subtilis*.
25

26. The organism of claim 23, wherein at least one of said genes is a *yaaD* gene.
30

27. The organism of claim 23, wherein at least one of said genes is a *yaaE* gene.

28. The organism of claim 23, wherein at least two of said genes are
35 *yaaD* and *yaaE* genes.

- 46 -

29. The organism of claim 23, wherein said organism is a *Bacillus* strain.
30. The organism of claim 23, wherein said organism is *Bacillus subtilis*.
31. The organism of claim 23, wherein said organism is *Escherichia coli*.
32. The organism of claim 19, wherein said genes are selected from the group consisting of *E. coli epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH* or *dxs*.
33. The organism of any one of claims 19-30, wherein said organism is grown in a liquid culture and the total B6 vitamer concentration in the culture supernatant is at least 7.0 mg/liter.
34. A method of producing a B6 vitamer comprising culturing a microorganism that has been genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism, under conditions such that the B6 vitamer is produced.
35. The method of claim 34, wherein said enzyme is one or more of YaaD or YaaE.
36. The method of claim 34, wherein at least one of said genes is a *yaaD* gene.
37. The method of claim 34, wherein at least one of said genes is a *yaaE* gene.
38. The method of claim 34, wherein said genes are contained on the *yaaDE* operon.
39. The method of claim 34, wherein the B6 vitamer is pyridoxine.

- 47 -

40. The method of claim 34, wherein the B6 vitamer is pyridoxal.
41. The method of claim 34, wherein the B6 vitamer is pyridoxamine.
- 5 42. The method of claim 34, wherein said genes are bacterial-derived.
43. The method of claim 34, wherein said genes are derived from *Bacillus*.
- 10 44. The method of claim 34, wherein said genes are derived from *Bacillus subtilis*.
- 15 45. The method of claim 34, wherein the microorganism is Gram positive.
46. The method of claim 34, wherein the microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*.
- 20 47. The method of claim 34, wherein the microorganism is of the genus *Bacillus*.
48. The method of claim 34, wherein the microorganism is *Bacillus*
- 25 *subtilis*.
49. The method of claim 34, further comprising recovering the B6 vitamer.
- 30 50. A method of producing a B6 vitamer comprising culturing a microorganism that overexpresses at least one *Bacillus* B6 vitamer biosynthetic gene under conditions such that the B6 vitamer is produced.
51. The method of claim 50, wherein the microorganism
- 35 overexpresses at least one *Bacillus subtilis* B6 vitamer biosynthetic enzyme.
52. The method of claim 50, wherein the B6 vitamer is pyridoxine.

53. The method of claim 50, wherein the B6 vitamer is pyridoxal.
54. The method of claim 50, wherein the B6 vitamer is pyridoxamine.
55. The method of claim 50, wherein the microorganism overexpresses at least two B6 vitamer biosynthetic enzymes.
56. The method of claim 50, wherein the microorganism is Gram positive.
57. The method of claim 50, wherein the microorganism is Gram negative.
58. The method of claim 50, wherein the microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*.
59. The method of claim 50, wherein the microorganism is of the genus *Bacillus*.
60. The method of claim 50, wherein the microorganism is *Bacillus subtilis*.
61. The method of claim 50, further comprising recovering the B6 vitamer.
62. A recombinant microorganism that overexpresses at least one *Bacillus* B6 vitamer biosynthetic gene.
63. A recombinant microorganism that overexpresses at least one *Bacillus* B6 vitamer biosynthetic enzyme.
64. The method of claim 63, wherein said enzyme is YaaD or YaaE.
65. The recombinant microorganism of claim 62 that overexpresses at least one *Bacillus subtilis* B6 vitamer biosynthetic gene.

66. The recombinant microorganism of claim 62, wherein the B6 vitamer biosynthetic gene is selected from the group consisting of *yaaD* and *yaaE*.
- 5 67. The recombinant microorganism of claim 62, that is Gram positive.
68. The recombinant microorganism of claim 62, belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium*, *Lactobacillus*,
10 *Lactococci* and *Streptomyces*.
69. The recombinant microorganism of claim 62 belonging to the genus *Bacillus*.
- 15 70. The recombinant microorganism of claim 62 which is *Bacillus subtilis*.
71. A recombinant microorganism selected from the group consisting of PX14 and PX17.
20
72. A vector comprising a nucleic acid sequence that encodes at least one *Bacillus* B6 vitamer biosynthetic gene operably linked to regulatory sequences.
73. The vector of claim 72, comprising a nucleic acid sequence that
25 encodes at least one *Bacillus subtilis* B6 vitamer biosynthetic gene.
74. The vector of claim 72, wherein the regulatory sequences comprise a constitutively active promoter.
- 30 75. The vector of claim 72, wherein the constitutively active promoter comprises P_{15} (SEQ ID NO:9) or P_{26} (SEQ ID NO:10) sequences.
76. The vector of claim 72, wherein the regulatory sequences comprise at least one artificial ribosome binding site (RBS).
35
77. A vector selected from the group consisting of pDX14R and pDX17R.

78. A recombinant microorganism comprising the vector of claim 72.
79. An isolated nucleic acid molecule that encodes at least one
5 *Bacillus* B6 vitamer biosynthetic gene.
80. The isolated nucleic acid molecule of claim 79 that encodes at
least one *Bacillus subtilis* B6 vitamer biosynthetic gene.
- 10 81. An isolated *Bacillus* B6 vitamer biosynthetic enzyme polypeptide.
82. An isolated *Bacillus subtilis* B6 vitamer biosynthetic enzyme
polypeptide.

Figure 1




Figure 3





Figure 4. Structure of pDX1F

Figure 5. Structure of pDX11F




Figure 6





FIGURE 7. Structure of pDX17R



SEQUENCE LISTING

<110> Omnigene Bioproducts, Inc., et al.

<120> METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS

<130> BGI-152PC

<150> 60/367089

<151> 2002-03-22

<150> 60/367863

<151> 2002-03-25

<150> 60/368618

<151> 2002-03-29

<160> 27

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 1

ccctctagag gaggagaaaa catggctcaa acaggtactg aacgtg

46

<210> 2

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 2

cccggatcct caactgtttt atacaagtgc cttttgctta tattc

45

<210> 3

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 3

ccctctagag gaggagacat aatggaacgt acaacgaatt ttaacgcag

49

<210> 4

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 4

cccggatccc ggacggtttg catagccaga ctttttactc a

41

<210> 5

<211> 5322

<212> DNA

<213> Artificial Sequence

<220>

<223> plasmid - pDX1F

<400> 5

tgccgcgcta	cagggcgcg	ccattcgcca	ttcaggctgc	gcaactgttg	ggaagggcga	60
tcgggtcg	cctcttcg	attacgccag	ctggcgaaag	ggggatgtgc	tgcaaggcga	120
ttaagttggg	taacgccagg	gttttcccag	tcacgacgtt	gtaaaacgac	ggccagtga	180
ttgtaatacg	actcactata	gggcgaattg	ggcccgacgt	cgcattgtcc	cgcccgccat	240
ggccgcggga	tccctctaga	ggaggagaaa	acatggctca	aacagggtact	gaacgtgtaa	300
aacgcggaat	ggcagaaatg	caaaaaggcg	gcgtcatcat	ggacgtcatc	aatgcggaac	360
aagcgaat	cgctgaagaa	gctggagctg	tcgctgtaat	ggcgctagaa	cgtgtgccag	420
cagatattcg	cgcggtcgga	ggagttgccc	gtatggctga	ccctacaatc	gtggaagaag	480
taatgaatgc	agtatctatc	ccggtaatgg	caaaagcgcg	tatcggacat	attgttgaag	540
cgctgtgtgc	tgaagctatg	ggtgttgact	atattgatga	aagtgaagtt	ctgacgccgg	600
ctgacgaaga	atttcattta	aataaaaaatg	aatacacagt	tccttttgtc	tgtggctgcc	660
gtgatcttgg	tgaagcaaca	cgccgtattg	cggaagggtgc	ttctatgctt	cgcacaaaag	720
gtgagcctgg	aacaggtaat	attgttgagg	ctgttcgcca	tatgcgtaaa	gttatcacta	780
gtgcggccgc	ctgcaggctg	accatatggg	agaggcgccg	gcgtcgacca	atagttaccc	840
ttattatcaa	gataagaaag	aaaaggattt	ttcgctacgc	tcaaaccctt	taaaaaaaca	900
caaaagacca	cattttttta	tgtggtcctt	attcttcaac	taaagcacc	attagttcaa	960
caaacgaaaa	ttggataaag	tgggatattt	ttaaaatata	tatttatgtt	acagtaatat	1020
tgacttttaa	aaaaggattg	attctaata	agaaagcaga	caagtaagcc	tcctaaattc	1080
acttttagata	aaaatttagg	aggcatatca	aatgaacttt	aataaaattg	atttagacaa	1140
ttggaagaga	aaagagatat	ttaatcatta	tttgaaccaa	caaacgactt	ttagtataac	1200
cacagaaatt	gatatttagt	ttttataacc	aaacataaaa	caagaaggat	ataaatttta	1260
ccctgcattt	attttcttag	tgacaagggt	gataaaactca	aatacagctt	ttagaactgg	1320
ttacaatagc	gacggagagt	taggttattg	ggataagtta	gagccacttt	atacaatttt	1380
tgatgggtga	tctaaaacat	tctctgggat	ttggactcct	gtaaagaatg	acttcaaaga	1440
gttttatgat	ttataccttt	ctgatgtaga	gaaatataat	ggttcgggga	aattgtttcc	1500
caaaacacct	atacctgaaa	atgctttttc	tctttctatt	attccatgga	cttcatttac	1560
tgggtttaac	ttaaatatca	ataataatag	taattacctt	ctaccattta	ttacagcagg	1620
aaaattcatt	aataaaggta	attcaatata	tttaccgcta	tctttacagg	tacatcatte	1680
tgtttgtgat	ggttatcatg	caggattggt	tatgaactct	attcaggaat	tgtcagatag	1740
gcctaattgac	tggcttttat	aatatgagat	aatgccgact	gtacttttta	cagtcggttt	1800
tctaattgtca	ctaacctgcc	ccgttagattg	agaagggttt	ttatattaca	gctccgggtac	1860
cgggctccca	acgcgttgga	tgcatagctt	gagtaattcta	tagtgtcacc	taaatagctt	1920
ggcgtaataca	tggatcatagc	tgtttctgtg	gtgaaattgt	tatccgaaca	ataggtgtac	1980
taggacttca	aggagcagtt	agagagcaca	tccatgcgat	tgaagcatgc	ggcgcggtcg	2040
gtcttgtcgt	aaaacgtccg	gagcagctga	acgaagtgtga	cggttgatt	ttgccggg	2100
gtgagagcac	gacgatgcgc	cgtttgatcg	atacgtatca	attcatggag	ccgcttcgtg	2160
aattcgctgc	tcagggcaaa	ccgatgtttg	gaacatgtgc	cggattaatt	atattagcaa	2220
aagaaattgc	cggttcagat	aatcctcatt	taggtcttct	gaatgtgggt	gtagaacgta	2280
attcatttgg	ccggcaggtt	gacagctttg	aagctgattt	aacaattaaa	ggcttggacg	2340
agccttttac	tggggatattc	atccgtgctc	cgcataattt	agaagctggt	gaaaatgttg	2400
aagttctatc	ggagcataat	ggtcgtattg	tagccgcgaa	acaggggcaa	ttccttggtc	2460
gctcattcca	tccggagctg	acagaagatc	accgagtgac	gcagctgttt	gttgaaatgg	2520
ttgaggaata	taagcaaaag	gcacttgtat	aaaacagtgtg	aggatccggg	atcactagtg	2580

cggccgcctg caggtcgacc atatgggaga gctcccaacg cgttggatgc atagcttgag 2640
tattctatag tgtcacctaa atagcttggc gtaatcatgg tcatagctgt ttctgtgtg 2700
aaattgttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaagc 2760
ctgggggtgcc taatgagtga gctaactcac attaattgcg ttgcgctcac tgcccgttt 2820
ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg cggggagagg 2880
cggtttgctg attgggcgct cttccgcttc ctgcgtcact gactcgctgc gctcggctcg 2940
tcggctgcgg cgagcggat cagctcactc aaaggcggta atacggttat ccacagaatc 3000
aggggataaac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa 3060
aaaggccgcg ttgctggcgt ttttcgatag gctccgcccc cctgacgagc atcacaaaaa 3120
tcgacgtca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc 3180
ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc 3240
cgcctttctc ccttcgggaa gcgtggcgtt ttctcatagc tcacgctgta ggtatctcag 3300
ttcgggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga 3360
ccgctgcgcc ttatccggta actatcgtct tgagccaac ccggaagac acgacttatc 3420
gccactggca gcagccactg gtaacaggat tagcagagc aggtatgtag gcgggtgtac 3480
agagttcttg aagtgggtgc ctaactacgg ctacactaga aggacagtat ttggtatctg 3540
cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaaa 3600
aaccaccgct ggtagcgggt gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa 3660
aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt ggaacgaaaa 3720
ctcacgttaa gggattttg tcatgagatt atcaaaaagg atcttcacct agatcctttt 3780
aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagtaaactt ggtctgacag 3840
ttaccaatgc ttaatcagtg aggcacctat ctacgcgac tgtctatttc gttcatccat 3900
agttgcctga ctccccgtcg ttagataaac tacgatacgg gagggcttac catctggccc 3960
cagtgctgca atgataccg gagaccacg ctacccggct ccagatttat cagcaataaa 4020
ccagccagcc ggaagggccg agcgagaag tggctctgca actttatccg cctccatcca 4080
gtctattaat tgttgccggg aagctagagt aagtagttcg ccagttaata gtttgcgcaa 4140
cgttggtggc attgctacag gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt 4200
cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc 4260
ggtttagctc ttccggctctc cgatcgttgt cagaagtaag ttggccgcag tggtatcact 4320
catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgcttttc 4380
tgtgactggt gagtactcaa ccaagtcatt ctgagaatac cgcgcccggc gaccgagttg 4440
ctcttgcccc gcgtcaatac gggataatag tgtatgacat agcagaactt taaaagtgtc 4500
catcttgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc 4560
cagttcgatg taaccactc gtgcaccaa ctgatcttca gcatctttta ctttcaccag 4620
cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa taagggcgac 4680
acggaaatgt tgaatactca tactcttctt ttttcaatat tattgaagca tttatcaggg 4740
ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaataggggt 4800
tccgcgcaca tttccccgaa aagtgccacc tgtatgcggt gtgaaatacc gcacagatgc 4860
gtaaggagaa aataccgcat caggcgaaat tgtaaacggt aatattttgt taaaattcgc 4920
gttaaatatt tgtaaatca gctcattttt taaccaatag gccgaaatcg gcaaaatccc 4980
ttataaatca aaagaataga ccgagatagg gttgagtgtt gttccagttt ggaacaagag 5040
tocactatta aagaacgtgg actccaacgt caaagggcga aaaaccgtct atcagggcga 5100
tgggccacta cgtgaaccat cacccaaatac aagttttttg cggctcgaggt gccgtaaagc 5160
tctaaatcgg aaccctaaag ggagcccccg atttagagct tgacggggaa agccggcgaa 5220
cgtggcgaga aaggaaggga agaaagcgaa aggagcgggc gctagggcgc tggcaagtgt 5280
agcggtcacg ctgcgcgtaa ccaccacacc cgccgcgctt aa 5322

<210> 6

<211> 5297

<212> DNA

<213> Artificial Sequence

<220>

<223> plasmid - pDX11F

<400> 6

tgccgcccgt	cagggcgcggt	ccatttcgcc	ttcaggctgc	gcaactgttg	ggaagggcga	60
tcgggtgcggg	cctcttcgct	attacgccag	ctggcgaaag	ggggatgtgc	tgcaaggcga	120
ttaagttggg	taacgccagg	gttttcccag	tcacgacgtt	gtaaaacgac	ggccagtga	180
ttgtaatacg	actcactata	gggcgaattg	ggcccgacgt	cgcatgctcc	cggccgccat	240
ggccgcggga	tccctctaga	ggaggagaca	taattggaacg	tacaacgaat	tttaacgcag	300
gtcctgcagc	gctgccactg	gaagtctctgc	aaaaagcaca	gaaagaattt	attgatttta	360
acgaatccgg	catgtctgtt	atggagcttt	cccaccgcag	caaagagtat	gaagcgggtg	420
accaaaaagc	gaaaagcctc	ttaatcgaac	tgatgggcat	tccggaagat	tacgatatct	480
tgttttcttca	aggcggggca	agccttcaat	tctcaatgct	tccgatgaac	tttttaacac	540
ctgaaaaaac	cgcacatttt	gtgatgaccg	gcgcttggtc	tgaaaaagca	ctggcagaaa	600
cgaactgtt	cgggaacacg	tctatcaccg	ctacaagtga	aacagacaat	tacagttata	660
ttccagaggt	tgaccttacg	gatgtaaaag	acggcgcata	tttacataatc	acatccaaca	720
atacaatttt	cggcactcag	tggcaggagt	ttccgaattc	tccaattccg	ctcgtagccg	780
acatgtccag	cgatatttta	agcagaaaaa	tcgatgtgtc	caaatttgat	gtgatctacg	840
gaggcatcac	tagtgcgcc	gcctgcaggt	cgaccatag	ggagaggcgg	cgcgctcgac	900
caatagttac	ccttattatc	aagataagaa	agaaaaggat	ttttcgctac	gctcaaattc	960
tttaaaaaaa	cacaaaagac	cacatttttt	aatgtggtct	ttattcttca	actaaagcac	1020
ccattagttc	aacaaacgaa	aattggataa	agtgggatat	ttttaaaata	tatattttatg	1080
ttacagtaat	attgactttt	aaaaaaggat	tgattctaata	gaagaaagca	gacaagtaag	1140
cctcctaaat	tcacttttaga	taaaaattta	ggaggcatat	caaatagaact	ttataaaaaat	1200
tgatttagac	aattggaaga	gaaaagagat	atttaatacat	tatttgaacc	aacaaacgac	1260
tttagtata	accacagaaa	ttgatattag	tgttttatac	cgaaacataa	aacaagaagg	1320
atataaattt	taccttgcat	ttattttctt	agtgaacagg	gtgataaact	caaatacagc	1380
ttttagaact	ggttacaata	gcgacggaga	gttaggttat	tgggataagt	tagagccact	1440
ttatacaatt	tttgatggtg	tatctaaaac	attctctggt	atttggaact	ctgtaaagaa	1500
tgacttcaaa	gagttttatg	atttatacct	ttctgatgta	gagaaatata	atggttccggg	1560
gaaattgttt	cccaaaacac	ctatacctga	aaatgctttt	tctcttttcta	ttattccatg	1620
gacttcattt	actgggttta	acttaaatat	caataataat	agtaattacc	ttctacccat	1680
tattacagca	ggaaaattca	ttaataaagg	taattcaata	tatttaccgc	tatctttaca	1740
ggtacatcat	tctgtttgtg	atggttatca	tgcaggattg	tttatgaact	ctattcagga	1800
attgtcagat	aggcctaata	actggctttt	ataatatgag	ataatgccga	ctgtactttt	1860
tacagtcggt	tttctaattg	cactaacctg	ccccgttagt	tgaagaagg	ttttatatta	1920
cagctccggt	accgggctcc	caacgcgttg	gatgcatagc	ttgagtatte	tatagtgtca	1980
cctaaatagc	ttggcgtaat	catggtcata	gctgtttcct	gtgtgaaatt	gttatccgta	2040
gtcatcatga	aaaaaagctg	gctgcaaaat	gaaaatgcga	acgtcccaaa	aatcttgaaa	2100
tattccacgc	atgtcaaagc	ggattcactc	tacaacactc	cgcgcacatt	tgcgatttat	2160
atgctgagcc	tcgttctgga	atggctcaag	gaaaacggcg	gtgtggaagc	tggtgaacag	2220
cgcaatgaac	aaaaagcgca	ggttctctac	agctgtattg	atgaaagcaa	cggcttctat	2280
aaaggacatg	ccagaaaaga	cagccgctca	cgcatgaatg	tcacattcac	gcttcgggat	2340
gacgaattaa	cgaaaacatt	cggtcagaaa	gcaaaagatg	cgaagatgat	cggccttggtc	2400
ggacaccgtt	cgggtgggagg	ctgccgcgct	tctatttata	acgcggtctc	tctcgaagac	2460
tgtgaaaaat	tagctgcgtt	catgaagaaa	ttccagcagg	aaaatgagta	aaaagtctgg	2520
ctatgcattc	cgtccgggat	ccgggatcac	tagtgcgcc	gcctgcagg	cgaccatatg	2580
ggagagctcc	caacgcgttg	gatgcatagc	ttgagtattc	tatagtgtca	cctaaatagc	2640
ttggcgtaat	catggtcata	gctgtttcct	gtgtgaaatt	gttatccgct	cacaattcca	2700
cacaacatac	gagccggaag	cataaagtgt	aaagcctggg	gtgcctaata	agtgaagctaa	2760
ctcacattaa	ttgcgttgcg	ctcactgccc	gctttccagt	cgggaaacct	gtcgtgccag	2820
ctgcattaat	gaatcggcc	acgcgcgggg	agaggcgggt	tgcgtatttg	gcgctcttcc	2880
gcttcctcgc	tactgactc	gctgcgctcg	gtcggtcgcc	tgccgagcgc	ggatcagct	2940
cactcaaagg	cggtaaatcg	gttatccaca	gaatcagggg	ataacgcagg	aaagaacatg	3000
tgagcaaaaag	gccagcaaaa	ggccaggaac	cgtaaaaagg	ccgcgttgct	ggcgtttttc	3060
gataggctcc	gccccctga	cgagcatcac	aaaaatcgac	gctcaagtca	gaggtggcga	3120
aaccgcgacg	gactataaag	ataccaggcg	tttccccctg	gaagctccct	cgtgcgctct	3180
cctgttccga	ccctgccgct	taccggatac	ctgtccgcct	ttctcccttc	gggaagcgtg	3240
gcgctttctc	atagctcacg	ctgtaggtat	ctcagttcgg	tgtaggtcgt	tcgctccaag	3300
ctgggctgtg	tgcacgaacc	ccccgttcag	cccgaccgct	gcgccttate	cggtaactat	3360
cgtcttgagt	ccaaccgggt	aagacacgac	ttatcgccac	tggcagcagc	cactggtaac	3420
aggattagca	gagcgaggta	tgtaggcggt	gctacagagt	tcttgaagtg	gtggcctaac	3480

tacggctaca ctagaaggac agtatttgggt atctgcgctc tgctgaagcc agttaccttc 3540
ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag cgggtggtttt 3600
tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc 3660
ttttctacgg ggtctgacgc tcagtggaaac gaaaactcac gttaaaggat tttgggtcatg 3720
agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag ttttaaataca 3780
atctaaagta tatatgagta aacttgggtc gacagttacc aatgcttaat cagtgaaggca 3840
cctatctcag cgatctgtct atttoggttc tccatagttg cctgactccc cgtcgtgtag 3900
ataactacga tacgggaggc cttaccatct ggccccagtg ctgcaatgat accgcgagac 3960
ccacgctcac cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc 4020
agaagtggct ctgcaacttt atccgcctcc atccagctc ttaattgttg ccgggaagct 4080
agagtaagta gttcgccagt taatagtttg cgcaacggtg ttggcattgc tacaggcatc 4140
gtggtgtcac gctcgtcgtt tgggtatggc tcattcagct ccggttccca acgatcaagg 4200
cgagttacat gatcccccat gttgtgcaaa aaagcgggta gctccttcgg tcctccgatc 4260
gttgtcagaa gtaagttggc cgcagtgtta tcactcatgg ttatggcagc actgcataat 4320
tctcttactg tcatgccatc cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag 4380
tcattctgag aataccgcgc ccggcgaccg agttgctctt gcccggcgtc aatacgggat 4440
aatagtgtat gacatagcag aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg 4500
cgaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca 4560
cccaactgat cttcagcatc ttttactttc accagcgttt ctgggtgagc aaaaacagga 4620
aggcaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatggtgaat actcatactc 4680
ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag cggatacata 4740
tttgaatgta tttagaaaaa taaacaaata ggggttcgc gcacatttcc ccgaaaagtg 4800
ccacctgtat gcggtgtgaa ataccgcaca gatgcgtaag gagaaaatac cgcatacaggc 4860
gaaattgtaa acgttaatat tttgttaaaa ttcgcgttaa atatttgta aatcagctca 4920
ttttttaacc aataggccga aatcggcaaa atcccttata aatcaaaaga atagaccgag 4980
atagggttga gtgttgttcc agtttggaaac aagagtccac tattaaagaa cgtggactcc 5040
aacgtcaaag ggcgaaaaac cgtctatcag ggcgatggcc cactacgtga accatcacc 5100
aaatcaagtt ttttgcggtc gaggtgccgt aaagctctaa atcggaaccc taaagggagc 5160
ccccgattta gagcttgacg gggaaagccg gcgaacgtgg cgagaaagga agggaaagaa 5220
gcgaaaggag cgggcgctag ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc 5280
acaccgcgcg cgcttaa 5297

<210> 7

<211> 6731

<212> DNA

<213> Artificial Sequence

<220>

<223> plasmid - pDX14R

<400> 7

ttgcggccgc ttcgaaagct gtaatatataa aaccttcttc aactaacggg gcagggttagt 60
gacattagaa aaccgactgt aaaaagtaca gtcggcatta tctcatatta taaaagccag 120
tcattaggcc tatctgacaa ttcctgaata gagttcataa acaatcctgc atgataacca 180
tcacaaacag aatgatgtac ctgtaaaagat agcggtaaat atattgaatt acctttatta 240
atgaattttc ctgctgtaat aatgggtaga aggttaattac tattattatt gatatttaag 300
ttaaaccacg taaatgaagt ccatggaata atagaaagag aaaaagcatt ttcagggtata 360
gggtgttttg gaaacaattt ccccgaaaca ttatatcttct ctacatcaga aagggtataaa 420
tcataaaaact ctttgaagtc attcttttaca ggagtccaaa taccagagaa tgttttagat 480
acaccatcaa aaattgtata aagtggctct aacttatccc aataacctaa ctctccgctg 540
ctattgtaac cagttctaaa agctgtatct gagtttatca cccttgctac taagaaaata 600
aatgcagggt aaaatttata tccttcttct tttatgtttc ggtataaaac actaatatca 660
atttctgtgg ttatactaaa agtcgtttgt tggttcaaat aatgattaaa tatctctttt 720
ctcttccaat tgtctaaatc aattttatta aagttcattt gatatgcctc ctaaaatttt 780
atctaaagtg aatttaggag gcttacttgt ctgctttctt cattagaatc aatccttttt 840
taaaagtcaa tattactgta acataaatat atattttaaa aatatccac tttatccaat 900
tttcgtttgt tgaactaatg ggtgcttttag ttgaagaata aagaccacat taaaaaatgt 960

ggctcttttgt gtttttttaa aggatttgag cgtagcgaaa aatccttttc tttcttatct 1020
tgataataag ggtaactatt gaattcggta ccaagagttt gtagaaacgc aaaaaggcca 1080
tccgtcagga tggccttctg cttaatttga tgcctggcag tttatggcgg gcgtcctgcc 1140
cgccaccctc cgggccgttg cttecgcaacg ttcaaatccg ctcccggcgg atttgtccta 1200
ctcaggagag cgttcaccca caaacaacag ataaaacgaa aggcccgatc tttcgactga 1260
gcctttcggt ttatttgatg cctggcagtt ccctactctc gcatggggag accccacact 1320
accatcggcg ctacggcggt tcacttctga gttcggcatg gggtcagggt ggaccaccgc 1380
gctactgcgc ccaggcaaat tctgttttat cagaccggtt ctgctgtctg atttaactctg 1440
tatcaggctg aaaatcttct ctcacccgcc aaaacaggat cctcaactgt tttatacaag 1500
tgcttttgc ttatattcct caaccatttc aacaaacagc tgcgtcactc ggtgatcttc 1560
tgtcagctcc ggatggaatg agcagccaag gaattgcccc tgtttcgcgg ctacaatacg 1620
accattatgc tccgatagaa cttcaacatt ttcaccagct tctaaaatat gcggagcacg 1680
gatgaatacc ccagtaaaaag gctcgtccaa gcctttaatt gttaaatacag cttcaaagct 1740
gtcaacctgc cggccaaatg aattacgttc tacaaccaca ttcagaagac ctaaatgagg 1800
attatctgaa ccggcaattt cttttgctaa tataattaat ccggcacatg ttccaaacat 1860
cggtttgccc tgagcagcga attcacgaag cggctccatg aattgatacg tatcgatcaa 1920
acggcgcatc gtcgtgctct caccgcccgg caaaatcaac ccgtcaactt cgttcagctg 1980
ctccggacgt tttacgacaa gaccagccgc gccgcatgct tcaatcgcat ggatgtgctc 2040
tctaactgct ccttgaagtc ctagtacacc tattgttaac atgtcagcag cgtcctatg 2100
ttcttaccag ccgcttctct gcatacgctg ttctggaagt aagtttgaga tttcaatccc 2160
tttcattgca gtaccaagct cttttgacaa ctcagcgatt aatttgtaat cagtaaagtg 2220
agttgtgct tccacaattg ctttcgcaaa tttagcaggg ttgtctgatt taaaaatacc 2280
agaaccaaca aatactcgt cagcaccaag ctgcatcatg agagcagcat cagctggagt 2340
tgctacgccg ccagcggcaa agttaacgac aggaagcttg ccgtcttttt taatttgaag 2400
aagaagctcg taaggagcac ctagggtttt cgcttctgtc attagctcat cctcactcat 2460
cgcaactact ttgcgcactt gagcgtaaac tttacgcata tggcgaacag cctcaacaat 2520
attacctgtt ccaggctcac cttttgtgctg aagcatagaa gcaccttcgc caatacggcg 2580
tggtgcttca ccaagatcac ggcagccaca gacaaaagga actgtgtatt catttttatt 2640
taaataaagt tcttcgtcag ccggcgctcag aacttcactt tcatcaatat agtcaacacc 2700
catagcttca agcacacgcg cttcaacaat atgtccgata cgcgcttttg ccattaccgg 2760
gatagatact gcattcatta cttcttccac gattgtaggg tcagccatac gggcaactcc 2820
tccagccgcg cgaatatctg ctggcacacg ttctagcgcc attacagcga cagctccagc 2880
ttcttcagcg attttcgctt gttccgcatt gatgacgtcc atgatgacgc cgcctttttg 2940
catttctgccc attccgcgtt ttacacgttc agtacctgtt tgagccatgt tttctcctcc 3000
tctagacgt cctgctgttg ttaagattat tataccacac cttgtagata aagtcaacaa 3060
ctttttgcaa aatttttcag gaatttttagc agaggttggt ctggatgtag aacaaaacat 3120
ctttccgctc ttgtgctgtt aggatatctt tcttggaagc taggtaggcc tccagttatg 3180
gcagttgggt aaaaggaaac aaaaagaccg ttttcacaca aaacggctct tttcgatttc 3240
tttttacagt cacagccact tttgcaaaaa ccggacagct tcatgcctta taactgctgt 3300
ttcggctcac ctgcaggcat gcaagcttcg cgaagcggcc gccgacgcga ggctggatgg 3360
ccttccccat tatgattctt ctcgcttcgc gccgcatcgg gatgcccgcg ttgcaggcca 3420
tgctgtccag gcaggtagat gacgaccatc agggacagct tcaaggatcg ctccgcgctc 3480
ttaccagcct aacttcgatc actggaccgc tgatcgctac ggcgatttat gccgctcgg 3540
cgagcacatg gaacgggttg gcatggattg taggcgcgc cctatacctt gtctgcctcc 3600
ccgcttgctg tccgcttgca tggagccggg ccacctcgac ctgaatggaa gccggcggca 3660
cctcgctaac ggattcacca ctccaagaat tggagccaat caattcttgc ggagaactgt 3720
gaatgcgcaa accaaccctt ggcagaacat atccatcgcg tccgccatct ccagcagccg 3780
cacgcggcgc atctcgggca gcgttgggtc ctggccacgg gtgcgcatga tctgtctcct 3840
gtcgttgagg acccggttag gctggcgggg ttgccttact ggttagcaga atgaatcacc 3900
gatacgcgag cgaacgtgaa gcgactgctg ctgcaaaaac tctgcgacct gagcaacaac 3960
atgaatggct ttcggtttcc gtgtttctga aagtctggaa acgcggaagt cagcgccctg 4020
caccattatg ttccggatct gcatcgcagg atgtctgtgg ctaccctgtg gaacacctac 4080
atctgtatta acgaagcgct ggcattgacc ctgagtgatt tttctctggt cccgcgcgat 4140
ccataccgcc agttgtttac cctcacaacg ttccagtaac cgggcatgtt catcatcagt 4200
aaccgctatc gtgagcatcc tctctcggtt catcggtatc attaccccca tgaacagaaa 4260
ttccccctta cacggaggca tcaagtgacc aaacaggaaa aaaccgccct taacatggcc 4320
cgcttttatca gaagccagac attaacgctt ctggagaaac tcaacgagct ggacgcggat 4380
gaacaggcag acatctgtga atcgcttcac gaccacgctg atgagcttta ccgcagctg 4440
ctcgcgcggt tccggtgatga ccgtgaaaac ctctgacaca tgcagctccc ggagacgggtc 4500

acagcttgctc tgtaagcgga tgccggggagc agacaagccc gtcagggcgc gtcagcgggt 4560
gttggcgggt gtcggggcgc agccatgacc cagtcacgta gcgatagcgg agtgataact 4620
ggcttaacta tgccggcatca gagcagattg tactgagagt gcaccatatg cgggtgtgaaa 4680
taccgcacag atgcgtaagg agaaaatacc gcatcaggcg ctcttcgcgt tcctcgctca 4740
ctgactcgct gcgctcggtc gttcggctgc ggcgagcggg atcagctcac tcaaaggcgg 4800
taatacgggt atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc 4860
agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat aggctccgcc 4920
cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac ccgacaggac 4980
tataaagata ccaggcggtt cccctggaa gctccctcgt gcgctctcct gttccgaccc 5040
tgccgcttac cggataacct tccgccttcc tcccttcggg aagcgtggcg ctttctcata 5100
gctcacgctg taggtatctc agttcgggtg aggtcgttcg ctccaagctg ggctgtgtgc 5160
acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt cttgagtcca 5220
acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag 5280
cgaggtatgt agggcggtgt acagagttct tgaagtgggt gcctaactac ggctacacta 5340
gaaggacagt atttgggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg 5400
gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tgggtttttt gtttgcaagc 5460
agcagattac ggcgagaaaa aaaggatctc aagaagatcc tttgatcttt tctacggggt 5520
ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga ttatcaaaaa 5580
ggatcttcac ctagatcctt ttaaattaaa aatgaagttt taaatcaatc taaagtatat 5640
atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct atctcagcga 5700
tctgtctatt tcgttcatcc atagtgcct gactccccgt cgtgtagata actacgatac 5760
gggagggctt accatctggc ccagtgctg caatgatacc gcgagaccca cgctcaccgg 5820
ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgcaga agtggctcctg 5880
caactttatc cgcctccatc cagtctatta attgttgccg ggaagctaga gtaagtagtt 5940
cgccagttaa tagtttgccg aacgttggtg ccattgctgc aggcacgtg gtgtcacgct 6000
cgctggttgg tatggcttca ttcagctccg gttcccaacg atcaaggcga gttacatgat 6060
cccccatggt gtgcaaaaaa gcggttagct ccttcggtc tccgatcggt gtcagaagta 6120
agttggccgc agtggtatca ctcatgggta tggcagcact gcataattct cttactgtca 6180
tgccatccgt aagatgcttt tctgtgactg gtgagtactc aaccaagtca ttctgagaat 6240
agtgatgctg gcgaccgagt tgctcttgcc cggcgtaaat accgggataat accgcgccac 6300
atagcagaac tttaaaagtg ctcatcattg gaaaacgttc ttcggggcga aaactctcaa 6360
ggatcttacc gctgttgaga tccagttcga tgtaacccac tcgtgcaccc aactgatctt 6420
cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacaggaagg caaaatgccg 6480
caaaaaaggg aataaggggc acacggaaat gttgaatact catactcttc ctttttcaat 6540
attattgaag catttatcag ggttattgtc tcatgagcgg atacatattt gaatgtattt 6600
agaaaaataa acaaataggg gttccgcgca catttccccg aaaagtgcc cctgacgtct 6660
aagaaacatc tattatcatg acattaacct ataaaaatag gcgtatcacg aggccctttc 6720
gtcttcaaga a 6731

<210> 8

<211> 10181

<212> DNA

<213> Artificial Sequence

<220>

<223> plasmid - pDX17R

<400> 8

gaattttgcg gccgcttcga aagctgtaat ataaaaacct tcttcaacta acggggcagg 60
ttagtgacat tagaaaaccg actgtaaaaa gtacagtcgg cattatctca tattataaaa 120
gccagtcatt aggcctatct gacaattcct gaatagagtt cataaacaat cctgcatgat 180
aaccatcaca aacagaatga tgtacctgta aagatagcgg taaatatatt gaattacctt 240
tattaatgaa ttttcctgct gtaataatgg gtagaaggta attactatta ttattgatat 300
ttaagttaaa ccagtaaat gaagtccatg gaataataga aagagaaaaa gcattttcag 360
gtataggtgt tttgggaaac aatttccccg aaccattata tttctctaca tcagaaagggt 420
ataaatcata aaactctttg aagtcattct ttacaggagt ccaaatacca gagaatgttt 480
tagatacacc atcaaaaatt gtataaagtg gctctaactt atcccaataa cctaactctc 540

cgtcgctatt gtaaccagtt ctaaaagctg tatttgagtt tatcaccctt gtcactaaga 600
aaataaatgc agggtaaaat ttatatcctt cttgttttat gtttcggtat aaaacactaa 660
tatcaatttc tgtggttata ctaaaagtcg tttgttggtt caaataatga ttaaataatct 720
cttttctctt ccaattgtct aaatcaattt tattaaagtt catttgatat gcctcctaaa 780
tttttatcta aagtgaattt aggaggctta cttgtctgct ttcttcatta gaatcaatcc 840
ttttttaaaa gtcaatatta ctgtaacata aatatataat ttaaaaatat cccactttat 900
ccaatttttc tttgttgaaac taatgggtgc tttagttgaa gaataaagac cacattaaaa 960
aatgtgggtc tttgtgtttt tttaaaggat ttgagcgtag cgaaaaatcc ttttctttct 1020
tatcttgata ataagggtaa ctattgaatt cggtagcag agtttgtaga aacgcaaaaa 1080
ggccatccgt caggatggcc ttctgcttaa tttgatgcct ggcagtttat ggcgggctgc 1140
ctgcccgcga cctcggggc cgttgcttcg caacggtcaa atccgctccc ggcggatttg 1200
tcctactcag gagagcggtc accgacaaac aacagataaa acgaaaggcc cagtctttcg 1260
actgagcctt tcgttttatt tgatgcctgg cagttcccta ctctcgcatg gggagacccc 1320
acactaccat cggcgctacg gcgtttcact tctgagttcg gcattggggtc aggtgggacc 1380
accgcgctac tgccgccagg caaattctgt tttatcagac cgcttctgctg ttctgattta 1440
atctgtatca ggctgaaaat cttctctcat ccgccaacaa aggatcctca actgttttat 1500
acaagtgcct tttgcttata ttctcaacc atttcaacaa acagctgcgt cactcgggtga 1560
tcttctgtca gctccggatg gaatgagcag ccaaggaatt gccctctgtt cgcggctaca 1620
atacgaccat tatgtccga tagaacttca acattttcac cagcttctaa aatatgcgga 1680
gcacggatga ataccccgat aaaaggctcg tccaagcctt taattgttaa atcagcttca 1740
aagctgtcaa cctgccggcc aaatgaatta cgttctacaa ccacattcag aagacctaaa 1800
tgaggattat ctgaaccggc aatttctttt gctaataata ttaatccggc acatgttcca 1860
aacatcggtt tgccctgagc agcgaattca cgaagcggct ccatgaattg atacgtatcg 1920
atcaaacggc gcactgcgt gctctcaccg cccggcaaaa tcaacccgct aacttcgttc 1980
agctgctccg gacgttttac gacaagacca gccgcgcgc atgcttcaat cgcattggatg 2040
tgctctctaa ctgctccttg aagtcctagt acacctattg ttaacatgtc agcagcgctc 2100
ctatgttctt accagccgctg ttcttgcata cgctgttctg gaagtaagtt tgagatttca 2160
atccctttca ttgcagtacc aagctctttt gacaactcag cgattaattt gtaatcagta 2220
aagtgaagtt ttgcttccac aattgctttc gcaaatttag cagggttgctc tgatttaaaa 2280
ataccagaac caacaaatac tccgtcagca ccaagctgca tcatgagagc agcatcagct 2340
ggagttgcta cgccgccagc ggcaaagtta acgacaggaa gcttgccgctc ttttttaatt 2400
tgaagaagaa gctcgtaagg agcacctagg tttttcgctt ctgtcattag ctcatcctca 2460
ctcatcgcaa ctactttgctg cacttgagcg ttaactttac gcatatggcg aacagcctca 2520
acaatattac ctggtccagg ctcacctttt gtgcgaagca tagaagcacc ttccgcaata 2580
cggcgtgttg cttcaccaag atcacggcag ccacagacaa aaggaactgt gtattcattt 2640
ttattttaaat gaaattcttc gtcagccggc gtcagaactt cactttcatc aatatagtca 2700
acacccatag cttcaagcac acgcgcttca acaatatgtc cgatacgcgc ttttgccatt 2760
accgggatag atactgcatt cattacttct tccacgattg tagggctcagc catacgggca 2820
actcctccag ccgcgcgaat atctgctggc acacgttcta gcgccattac agcgacagct 2880
ccagcttctt cagcgatttt cgcttggtcc gcattgatga cgtccatgat gacgccgct 2940
ttttgcaatt ctgccattcc gcgttttaca cgttcagtag ctggttgagc catgttttct 3000
cctcctctag aacaggcggg gttgcccccg cctgtaatta aattattaca caccctgtag 3060
ggaaagtcaa tacctttttg taaaattttt acacagcgtg gatctcttct agggacacct 3120
ctttgtaccc ctcaaggag aaatattggc ggtactgagc acagtttttg ttggtggaca 3180
gtgaaccata gctgtcgtca atagcctcga gttatggcag ttggttaaaa ggaaacaaaa 3240
agaccgtttt cacacaaaac ggtctttttc gatttctttt tacagtcaca gccacttttg 3300
caaaaaccgg acagcttcat gccttataac tgctgtttcg gtcgacgatg atctgccgtt 3360
ttcttctgca agccaaaaaa ccttcggtta caacgagaag gattcttcac tttctaaagt 3420
tcggcgagtt tcatccctct gtcccagtcg ttttttggat caaggcagac tgctgcaatg 3480
tctatctatt ttaataatag gtgcagttcc caggcgatag tgcccaatgg aagtatacca 3540
aaatcaacgg gcttgtagca acacattagc ccaattcgat atcggcagaa tagatttttt 3600
taatgccttc gttcgtttct aaaagcagaa cgccttcac atctatacct aacgccttac 3660
cgtaaaaggt tccgtttaac gttctggctc tcatattagt gccaataccg agcgcatagc 3720
tttcccataa aagcttaatc ggcgtaaatc cgtgcgtcat ataatccgg taccgtttct 3780
caaagcatag taaaatatgc tggatgacgc cggcccgatc aattttttcc ccagcagctt 3840
ggctgaggct tgctcgcatg tccttcaatt catctggaaa atcattaggc tgctggttaa 3900
cgtaaatgcc gatcccaatg atcactgaac gtacgcggtc ttcttcagcc tgcatttccg 3960
ttaggatacc gactgttttt tttccgttaa tcaaaatc atttggccat ttaatatccg 4020
tttggatgcc tgctgcctct tctattccct gcacaacagc tactgcagca agcagagtca 4080

gctgcggtgt tttttggagc ggaatgtcag gccgcaaat caggctcacc caaacaccgt 4140
ttccttcttg agaatgccat accctagaca ttcggcccct tccggctgtt tgtttgtcag 4200
ccaccacaag ggtgccttcc ggtgcgttat tattcgcgag ctcatgagcc gttttttgcg 4260
tgcttgaaag aacgtcatgg taaataagat gctggcccat cacttccgtt tttaatccaa 4320
aacgaatttc gctttcactg agttttccgg gttttttgat gagccgatat ccttttcttc 4380
taacggcttc tacttcaata ccctctttcc gaagctcttc aatatgcttc cacacagcag 4440
ttcttgaaca gccgagagca tcaactgatt tttggccgga aataaattca ttgcccgcct 4500
gagaaaaata ttcaataagg tcttttctta atgttgaccg catgtcttca gccactcctc 4560
tatgtgtttc ttttgattgg agagcttccc tgtcacaaca gcctgtctga tccactgtaa 4620
ttcttctgac acccattttc cggccggccg gtttcgaagc gcaagcaagt ccttaccctg 4680
gatatacaaga tcttaaggc ttttgatcgg cagggttttg taagcgctact gaatgtcctt 4740
cagtttcttt tcatccagtt tttcgttttg ccgaagctgc gatatttttg ccgctgagag 4800
cagtgtcttt tcccagctc tgtacattgt cattgcgtca aggtctctggc caaacgtatc 4860
ggcaatgtga atggcttccct tgatcacttt tcccgggagc ttccaggctt tcaggaaaaa 4920
gggcgcgtct tcaaaaacta tgccaagggt aattaaaaga gcagcccaaa gctcctcacg 4980
ggatgttaaa gagaagaatg gaaactcact cgttgaaatc aggttttctc gtttatgata 5040
aaaaccagga agctcttcat acaatctcgt ttgaatgagt gtttgaagcg cctggcgaga 5100
agctcttccc tgcagcaatt tctcaaaact tctgttttcc ggtgaaagcg taaagccaag 5220
gaggagtgat ttttctttcg caatggcttc ttctgtttcc ggtgaaagcg taaagccaag 5280
ctggctcata aagcgtacgg ctctcagcat atcaatatct ttcttgccgc caaaataatc 5340
aggctttcca acggttcgaa tcaacttctg cgcattgatc gttaaatctc tgcgttttag 5400
aagcaccttc ccgtccgctg tcatggccat ttctgacggg cttctgaaat caacataatc 5460
atcctcttct aatgatgaga taaattgcac ttctgacggg tcccagagca caataatggg 5520
agattcagtc cggaatgtcg tgacttcata gggttcatcc cgttctactt gatcagggtgc 5580
cccgtgctct ttgcctacat caacagtcgg cgttcgcttc atatagctgt cacgaactgc 5640
cgcactgtgc gcgatatcga catctccgat cgttcgcttc atatagctgt cacgaactgc 5700
gcccccgaca aaataagcct gatggcccg cgttcgcttc atatagctgt cacgaactgc 5760
tttgataaaa actttttcca tgtgatcact ccggttctgc taaatcggca taaatctgtt 5820
catactggct gacaattttt ttagaagaaa attcattttc aagcatctct attgccgcct 5880
ttgtaaaacg attgcttagc tgttcatctt ctaaaatgct catcgccggg gctgttgccg 5940
ccgtaacatc accgacatcc accaaaaatc cgctcacatt gttttttata acctcaggga 6000
taccgccaat gtttgtttcca atacaaggca ctccgcaagc catcgcttca agcaggacaa 6060
ggccaaagct ttctttttcca gatagcagca gcttcaaatc gctaatagaa taaagatctt 6120
caacacggtc ttgatttcca agcattaaga cttggctctc caagccatat tttctgataa 6180
gtcgcagggc tgcgatttcc tccggaccgt ctccgactaa aagcagcttc gctttcggtt 6240
tgccagcgat attgcggaac acacggatga catcctgcac gcgtgcagcc actggtaaca 6300
ggattagcag agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggccctaact 6360
acggctacac tagaaggaca gtatttggtg tctgcgctct gctgaagcca gttaccttcg 6420
gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc ggtgggtttt 6480
ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct 6540
tttctacggg gtctgacgct cagtggaaac aaaaatcacg ttaagggaatt ttggtcatga 6600
gattatcaaa aaggatcttc acctagatcc ttttaaatga atgcttaatc agtgaggcac 6660
tctaaagtat atatgagtaa acttggtctg acagttacca ctgactcccc gtcgtgtaga 6720
ctatctcagc gatctgtcta tttcgttcat ccatagttgc tgcaatgata ccgcgagacc 6780
taactacgat acgggaggggc ttaccatctg gccccagtg taaaccagcc agccggaagg gccgagcgca 6840
cacgctcacc ggctccagat ttatcagcaa tccgcctcca tccagttctat taattgttgc cggaagcta 6900
gaagtggctc tgcaacttta tccgcctcca tccagttctat taattgttgc cggaagcta 6960
gagtaagtag ttcgccagtt aatagtttgc gcaacggtgt tgccattgct acaggcatcg 7020
tggtgtcacg ctctgcgttt ggtatggctt cattcagctc cggttcccaa cgatcaaggc 7080
gagttacatg atcccccatg ttgtgcaaaa aagcgggttag ctcttctggt cctccgatcg 7140
ttgtcagaag taagtggcc gcaagtgtat cactcatggt tatggcagca ctgcataatt 7200
ctcttactgt catgccatcc gtaagatgct tttctgtgac tggtagtagc tcaaccaagt 7260
cattctgaga atagtgtatg cggcgaccga gttgtctctg cccggcgctc atacgggata 7320
ataccgcgcc acatagcaga actttaaaag tgcctcatcat tggaaaacgt tcttcggggc 7380
gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaacct actcgtgcac 7440
ccaactgatc ttcagcatct tttactttca ccagcggttc tgggtgagca aaaacaggaa 7500
ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa atgttgaata ctcatactct 7560
tcctttttca atattattga agcatttatc agggttattg tctcatgagc ggatacatat 7620
ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc cgaaaagtgc

```

cacctgacgt ctaagaaacc attattatca tgacattaac ctataaaaat aggcgtatca 7680
cgaggccctt tcgtctcgca tgcggatcag tgagggtttg caactgcggg tcaaggatct 7740
ggatttcgat cacggcacga tcatcgtgcg ggagggcaag ggctccaagg atcgggcctt 7800
gatgttacct gagagcttgg caccagcct gcgcgagcag gggaattgat ccggtggatg 7860
accttttgaa tgacctttaa tagattatat tactaattaa ttggggaccc tagaggtccc 7920
cttttttatt ttaaaaattt tttcacaaaa cgggtttacaa gcataacggg ttttgcctgc 7980
cgcaaacggg ctgttctggg gttgctagtt tgttatcaga atcgagatc cggcttcagg 8040
tttgccgggt gaaagcgcta tttcttcag aattgccatg attttttccc cacgggaggc 8100
gtcactggct cccgtgttgt cggcagcttt gattcgataa gcagcatcgc ctgtttcagg 8160
ctgtctatgt gtgactgttg agctgtaaca agttgtctca ggtgttcaat ttcattgtct 8220
agttgctttg ttttactggg ttcacctgtt ctattaggtg ttacatgctg ttcattctgt 8280
acattgtcga tctgttcatt gtgaacagct ttaaattgcac caaaaactcg taaaagctct 8340
gatgtatcta tcttttttac accgttttca tctgtgcata tggacagttt tccctttgat 8400
atctaaccgg gaacagttgt tctacttttg tttgttagtc ttgatgcttc actgatagat 8460
acaagagcca taagaacctc agatccttcc gtatttagcc agtatgttct ctagtgtgg 8520
tcgttgtttt tgcgtgagcc atgagaacga accattgaga tcatgcttac tttgcattgc 8580
actcaaaaaa tttgcctcaa aactgggtgag ctgaattttt gcagttaaag catcgtgtag 8640
tgtttttctt agtccgttac gtaggtagga atctgatgta atggttgttg gtattttgtc 8700
accattcatt tttatctggg tgttctcaag ttcgggttac agatccattt gtctatctag 8760
ttcaacttgg aaaatcaacg tatcagtcgg gcggcctcgc ttatcaacca ccaatttcat 8820
attgctgtaa gtgttttaaa ctttacttat tggtttcaaa acccattggg taagcctttt 8880
aaactcatgg tagttatttt caagcattaa catgaactta aattcatcaa ggctaattct 8940
tatatttgcc ttgtgagttt tcttttgtgt tagttctttt aataaccact cataaatcct 9000
catagagtat ttgttttcaa aagacttaac atgttccaga ttatatttta tgaatttttt 9060
taactggaaa agataaggca atattctctc actaaaaact aattctaatt tttcgcttga 9120
gaacttggca tagtttgtcc actggaaaat ctcaaagcct ttaaccaaag gattcctgat 9180
ttccacagtt ctcgtcatca gctctctggg tgcttttagc aatacaccat aagcattttc 9240
cctactgatg ttcattcatc gagcgtattg gttataagtg aacgataccg tccgttcttt 9300
cctgttaggg ttttcaatcg tggggttgag tagtgccaca cagcataaaa ttagcttggg 9360
ttcatgctcc gtttaagtc atgcgactaat cgctagttca tttgctttga aaacaactaa 9420
ttcagacata catctcaatt ggtctaggtg attttaatca ctataccaat tgagatgggc 9480
tagtcaatga taattactag tctttttcct ttgagttgtg ggtatctgta aattctgcta 9540
gacctttgct ggaaaacttg taaattctgc tagacctct gttaaattccg ctgacctttt 9600
gtgtgttttt tttgtttata ttcaagtggg tataatttat agaataaaga aagaataaaa 9660
aaagataaaa agaataagat ccagccctgt gtataactca ctacttttagt cagttccgca 9720
gtattacaaa aggatgtcgc aaacgctgtt tgctcctcta caaaacagac cttaaaaccc 9780
taaaggctta agtagcacc tcgcaagctc gggcaaatcg ctgaatattc cttttgtctc 9840
cgaccatcag gcacctgagt cgctgtcttt ttcgtgacat tcagttcgct gcgctcacgg 9900
ctctggcagt gaatgggggt aaatggcact acagggcctt tttatggatt catgcaagga 9960
aactaccat aatacaagaa aagcccgtca cgggcttctc agggcgtttt atggcggttc 10020
tgctatgtgg tgctatctga ctttttgcgt ttcagcagtt cctgcccctc gattttccg 10080
tctgaccact tcggattatc ccgtgacagg tcattcagac tggctaattgc acccagtaag 10140
gcagcggtat catcaacagg cttaccctgc ttactgtcaa c 10181

```

<210> 9

<211> 194

<212> DNA

<213> Artificial Sequence

<220>

<223> promoter sequence

<400> 9

```

gctattgacg acagctatgg ttcactgtcc accaaccaaa actgtgctca gtaccgcaa 60
tattttctccc ttgaggggta caaagagggtg tccctagaag agatccacgc tgtgtaaaaa 120
ttttacaaaa aggtattgac tttccctaca ggggtgtgtaa taatttaatt acaggcgagg 180
gcaacccccg ctgt 194

```

<210> 10
<211> 163
<212> DNA
<213> Artificial Sequence

<220>
<223> promoter sequence

<400> 10
gcctacctag cttccaagaa agatatccta acagcacaag agcggaaaga tgttttgttc 60
tacatccaga acaacctctg ctaaaattcc tgaaaaattt tgcaaaaagt tggtgacttt 120
atctacaagg tgtggtataa taatcttaac aacagcagga cgc 163

<210> 11
<211> 127
<212> DNA
<213> Artificial Sequence

<220>
<223> promoter sequence

<400> 11
gaggaatcat agaattttgt caaaataatt ttattgacaa cgtcttatta acgttgatat 60
aatttaaatt ttatttgaca aaaatgggct cgtggtgtac aataaatgta gtgagggtgga 120
tgcaatg 127

<210> 12
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 12
gaaatcatat aactatacct tgattagggg gaccaagaaa tg 42

<210> 13
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 13
caagaacgcg gctggtgaaga acataggagc gctgctgaca tg 42

<210> 14
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 14
tctagaaagg aggtga 16

<210> 15
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 15
tctagaagga ggagaaaaca tg

<210> 16
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 16
tctagaggag gagaaaacat g

<210> 17
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 17
taagaacaaa ggaggagagc tgacatg

<210> 18
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 18
taagaacaga ggaggagagc tgacatg

<210> 19
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 19
taagaagaaa ggaggtgagc tgacatg

22

21

27

27

27

<210> 20

<211> 1282

<212> DNA

<213> *Bacillus subtilis*

<400> 20

```

ttaatcaatt gaaagagctc tgatggatgt tagggctctt tcgcgtaata tactgaaaaa 60
accaattttt taataaaaaa tgattttcaa agcgctaaaa accgaataaa atagtatata 120
tgcatatgaa ttattggatt tctaggatac aataaggatt agaaatcata taactatacc 180
ttgattaggg ggaccaagaa atggctcaaa caggctactga acgtgtaaaa cgcggaatgg 240
cagaaatgca aaaaggcggc gtcatcatgg acgtcatcaa tgcggaacaa gcgaaaatcg 300
ctgaagaagc tggagctgtc gctgtaatgg cgctagaacg tgtgccagca gatattcgcg 360
cggctggagg agttgcccgat atggctgacc ctacaatcgt ggaagaagta atgaatgcag 420
tatctatccc ggtaatggca aaagcgcgta tcggacatat tgttgaagcg cgtgtgcttg 480
aagctatggg tgttgactat attgatgaaa gtgaagttct gacgccggct gacgaagaat 540
ttcatttaaa taaaaatgaa tacacagttc cttttgtctg tggctgccgt gatcttggtg 600
aagcaacacg ccgtattgcg gaagggtgctt ctatgcttcg cacaaaaggt gagcctggaa 660
caggtaatat tgttgaggct gttcgccata tgcgtaaaagt taacgctcaa gtgcgcaaag 720
tagttgcgat gagtgaggat gagctaataa cagaagcgaa aaacctaggt gctccttacg 780
agcttcttct tcaaattaaa aaagacggca agcttctctg cgtaaacttt gccgctggcg 840
gcgtagcaac tccagctgat gctgctctca tgatgcagct tgggtgctgac ggagtatttg 900
ttggttctgg tattttttaa tcagacaacc ctgctaaatt tgcgaaagca attgtggaag 960
caacaactca ctttactgat tacaaattaa tcgctgagtt gtcaaaagag cttggtactg 1020
caatgaaagg gattgaaatc tcaaacttac ttccagaaca gcgtatgcaa gaacgcggct 1080
ggtaagaaca taggagcgct gctgacatgt taacaatagg tgtactagga cttcaaggag 1140
cagttagaga gcacatccat gcgattgaag catgcggcgc ggctggtctt gtcgtaaaac 1200
gtccggagca gctgaacgaa gttgacgggt tgattttgcc gggcggtgag agcacgacga 1260
tgcgccgttt gatcgatacg ta                                     1282

```

<210> 21

<211> 293

<212> PRT

<213> *Bacillus subtilis*

<400> 21

```

Ala Gln Thr Gly Thr Glu Arg Val Lys Arg Gly Met Ala Glu Met Gln
 1              5              10              15
Lys Gly Gly Val Ile Met Asp Val Ile Asn Ala Glu Gln Ala Lys Ile
      20      25      30
Ala Glu Glu Ala Gly Ala Val Ala Val Met Ala Leu Glu Arg Val Pro
      35      40      45
Ala Asp Ile Arg Ala Ala Gly Gly Val Ala Arg Met Ala Asp Pro Thr
      50      55      60
Ile Val Glu Glu Val Met Asn Ala Val Ser Ile Pro Val Met Ala Lys
      65      70      75      80
Ala Arg Ile Gly His Ile Val Glu Ala Arg Val Leu Glu Ala Met Gly
      85      90      95
Val Asp Tyr Ile Asp Glu Ser Glu Val Leu Thr Pro Ala Asp Glu Glu
      100      105      110
Phe His Leu Asn Lys Asn Glu Tyr Thr Val Pro Phe Val Cys Gly Cys
      115      120      125
Arg Asp Leu Gly Glu Ala Thr Arg Arg Ile Ala Glu Gly Ala Ser Met
      130      135      140
Leu Arg Thr Lys Gly Glu Pro Gly Thr Gly Asn Ile Val Glu Ala Val
      145      150      155      160
Arg His Met Arg Lys Val Asn Ala Gln Val Arg Lys Val Val Ala Met
      165      170      175
Ser Glu Asp Glu Leu Met Thr Glu Ala Lys Asn Leu Gly Ala Pro Tyr
      180      185      190

```


Glu Leu Leu Leu Gln Ile Lys Lys Asp Gly Lys Leu Pro Val Val Asn
 195 200 205
 Phe Ala Ala Gly Gly Val Ala Thr Pro Ala Asp Ala Ala Leu Met Met
 210 215 220
 Gln Leu Gly Ala Asp Gly Val Phe Val Gly Ser Gly Ile Phe Lys Ser
 225 230 235 240
 Asp Asn Pro Ala Lys Phe Ala Lys Ala Ile Val Glu Ala Thr Thr His
 245 250 255
 Phe Thr Asp Tyr Lys Leu Ile Ala Glu Leu Ser Lys Glu Leu Gly Thr
 260 265 270
 Ala Met Lys Gly Ile Glu Ile Ser Asn Leu Leu Pro Glu Gln Arg Met
 275 280 285
 Gln Glu Arg Gly Trp
 290

<210> 22

<211> 988

<212> DNA

<213> Bacillus subtilis

<400> 22

ctggtatttt taaatcagac aaccctgcta aatttgcgaa agcaattgtg gaagcaacaa 60
 ctcactttac tgattacaaa ttaatcgctg agttgtcaaa agagcttggt actgcaatga 120
 aagggattga aatctcaaac ttacttcag aacagcgat gcaagaacgc ggctggtaag 180
 aacataggag cgctgctgac atgttaacaa taggtgtact aggacttcaa ggagcagtta 240
 gagagcacat ccatgcgatt gaagcatgcg gcgcggctgg tcttgctgta aaacgtccgg 300
 agcagctgaa cgaagttgac ggggtgattt tgccgggctgg tgagagcacg acgatgcgcc 360
 gtttgatcga tacgtatcaa ttcattggagc cgcttcgtga attcgtgct cagggcaaac 420
 cgatgtttgg aacatgtgcc ggattaatta tattagcaaa agaaattgcc ggttcagata 480
 atcctcattt aggtccttctg aatgtgggtg tagaacgtaa ttcatttggc cggcaggttg 540
 acagctttga agctgattta acaattaaag gcttgacga gccttttact ggggtattca 600
 tccgtgctcc gcatatttta gaagctggtg aaaatggtga agttctatcg gagcataatg 660
 gtcgtattgt agccgcgaaa caggggcaat tccttggtg ctcattccat ccggagctga 720
 cagaagatca ccgagtgacg cagctgtttg ttgaaatggt tgaggaatat aagcaaaagg 780
 cacttgata aaacagttga aagctgtgga aacttatagt acattataag cacaaataaa 840
 gatcgaaaag cgttgatagg aactagtagg gagcctctct ttctaagaga gccgatggtt 900
 ggtgcgaatc ggtgaaagat gctgtctgaa tccatccttg agcgaaatgc tgaagcgagt 960
 aggcattttac gggataaccg ttatgttt 988

<210> 23

<211> 196

<212> PRT

<213> Bacillus subtilis

<400> 23

Met Leu Thr Ile Gly Val Leu Gly Leu Gln Gly Ala Val Arg Glu His
 1 5 10 15
 Ile His Ala Ile Glu Ala Cys Gly Ala Ala Gly Leu Val Val Lys Arg
 20 25 30
 Pro Glu Gln Leu Asn Glu Val Asp Gly Leu Ile Leu Pro Gly Gly Glu
 35 40 45
 Ser Thr Thr Met Arg Arg Leu Ile Asp Thr Tyr Gln Phe Met Glu Pro
 50 55 60
 Leu Arg Glu Phe Ala Ala Gln Gly Lys Pro Met Phe Gly Thr Cys Ala
 65 70 75 80
 Gly Leu Ile Ile Leu Ala Lys Glu Ile Ala Gly Ser Asp Asn Pro His
 85 90 95

Leu Gly Leu Leu Asn Val Val Val Glu Arg Asn Ser Phe Gly Arg Gln
 100 105 110
 Val Asp Ser Phe Glu Ala Asp Leu Thr Ile Lys Gly Leu Asp Glu Pro
 115 120 125
 Phe Thr Gly Val Phe Ile Arg Ala Pro His Ile Leu Glu Ala Gly Glu
 130 135 140
 Asn Val Glu Val Leu Ser Glu His Asn Gly Arg Ile Val Ala Ala Lys
 145 150 155 160
 Gln Gly Gln Phe Leu Gly Cys Ser Phe His Pro Glu Leu Thr Glu Asp
 165 170 175
 His Arg Val Thr Gln Leu Phe Val Glu Met Val Glu Glu Tyr Lys Gln
 180 185 190
 Lys Ala Leu Val
 195

<210> 24

<211> 990

<212> DNA

<213> Escherichia coli

<400> 24

atggttaaaa cccaacgtgt tgtgatcact cccggcgagc ccgcccgggat tggcccggac 60
 ttagttgtcc agcttgacaca gcgtgagtgg ccggtcgaac tggttgtttg tgccgatgcc 120
 actctcctta ccaaccgggc agcgatgctc ggtttgccgc tcaccctccg cccttattcc 180
 cccaactccc ctgcacaacc gcaaactgcg ggcacattaa cgctacttcc tgtcgcgcta 240
 cgtgcacctg tcaactgcggg gcagttagcg gttgaaaatg ggcattatgt ggtggaaacg 300
 ctggcgcgag cgtgcgatgg ttgtctgaac ggcgaatttg ccgcgctgat cacaggtccg 360
 gtgcataaag gcgttattaa cgacgctggc attcctttta ccggtcatac cgagtttttc 420
 gaagagcggt cgcaggcgaa aaaggtggtg atgatgctgg cgaccgaaga acttcgcgtg 480
 gcgctggcaa cgacgcattt accgctgcgc gatatcgag acgctatcac cctgcactt 540
 ttgcacgaag tgattgctat tttgcatcac gatttgcgga ccaaatttgg tattgccgaa 600
 ccgcgcattc tgggtctgcgg gctgaatccg cacgcgggcg aaggcggtca tatgggtacg 660
 gaagagatag acaccattat tccgggtgctc aatgagctgc gggcgcgagg gatgaaactc 720
 aacggggcgc tgcttgccga taccctgttt cagccgaaat atcttgataa cgccgacgcc 780
 gtgctggcga tgtaccacga tcagggtctt cccgtgctaa aataccaggg cttcggggcg 840
 ggtgtgaaca ttacgctggg cctgcccttt attcgcacat cagtggacca cggcaccgcg 900
 cttgaactgg cgggacgtgg caaagccgat gtcggcagtt ttattacggc gcttaatctc 960
 gccatcaaaa tgattgttaa cacccaatga 990

<210> 25

<211> 329

<212> PRT

<213> Escherichia coli

<400> 25

Met Val Lys Thr Gln Arg Val Val Ile Thr Pro Gly Glu Pro Ala Gly
 1 5 10 15
 Ile Gly Pro Asp Leu Val Val Gln Leu Ala Gln Arg Glu Trp Pro Val
 20 25 30
 Glu Leu Val Val Cys Ala Asp Ala Thr Leu Leu Thr Asn Arg Ala Ala
 35 40 45
 Met Leu Gly Leu Pro Leu Thr Leu Arg Pro Tyr Ser Pro Asn Ser Pro
 50 55 60
 Ala Gln Pro Gln Thr Ala Gly Thr Leu Thr Leu Leu Pro Val Ala Leu
 65 70 75 80
 Arg Ala Pro Val Thr Ala Gly Gln Leu Ala Val Glu Asn Gly His Tyr
 85 90 95

Val Val Glu Thr Leu Ala Arg Ala Cys Asp Gly Cys Leu Asn Gly Glu
 100 105 110
 Phe Ala Ala Leu Ile Thr Gly Pro Val His Lys Gly Val Ile Asn Asp
 115 120 125
 Ala Gly Ile Pro Phe Thr Gly His Thr Glu Phe Phe Glu Glu Arg Ser
 130 135 140
 Gln Ala Lys Lys Val Val Met Met Leu Ala Thr Glu Glu Leu Arg Val
 145 150 155 160
 Ala Leu Ala Thr Thr His Leu Pro Leu Arg Asp Ile Ala Asp Ala Ile
 165 170 175
 Thr Pro Ala Leu Leu His Glu Val Ile Ala Ile Leu His His Asp Leu
 180 185 190
 Arg Thr Lys Phe Gly Ile Ala Glu Pro Arg Ile Leu Val Cys Gly Leu
 195 200 205
 Asn Pro His Ala Gly Glu Gly Gly His Met Gly Thr Glu Glu Ile Asp
 210 215 220
 Thr Ile Ile Pro Val Leu Asn Glu Leu Arg Ala Gln Gly Met Lys Leu
 225 230 235 240
 Asn Gly Pro Leu Pro Ala Asp Thr Leu Phe Gln Pro Lys Tyr Leu Asp
 245 250 255
 Asn Ala Asp Ala Val Leu Ala Met Tyr His Asp Gln Gly Leu Pro Val
 260 265 270
 Leu Lys Tyr Gln Gly Phe Gly Arg Gly Val Asn Ile Thr Leu Gly Leu
 275 280 285
 Pro Phe Ile Arg Thr Ser Val Asp His Gly Thr Ala Leu Glu Leu Ala
 290 295 300
 Gly Arg Gly Lys Ala Asp Val Gly Ser Phe Ile Thr Ala Leu Asn Leu
 305 310 315 320
 Ala Ile Lys Met Ile Val Asn Thr Gln
 325

<210> 26

<211> 732

<212> DNA

<213> Escherichia coli

<400> 26

atggctgaat tactgttagg cgtcaacatt gaccatatcg ctacgctgcg caacgcgcgc 60
 ggtaccgctt acccgatcc ggtgcaggcc gcgtttattg ccgagcaggc gggagcggac 120
 ggcattaccg tgcatttacg tgaagatcgc cgtcacatta ctgaccgcga cgtgcgcac 180
 ctgcgtcaga cgctggatac ccgcatgaat ctggagatgg cggtgaccga agagatgctg 240
 gcgatcgccg ttgagacgaa gccacatttt tgctgcctgg taccggaaaa gcgtcaggaa 300
 gtaacaaccg aaggcggcct ggatgtcgca gggcagcgtg acaaaatgcg cgatgcctgc 360
 aaacgtcttg cagatgccgg gattcagggt tctctgttta ttgacgccga tgaagagcag 420
 atcaaagctg cggcagaggt tggcgcaccg tttatcgaga tccacaccgg ttgctatgct 480
 gatgccaaaa ctgacgccga acaggcgcaa gagctggcgc gtatcgccaa agccgcgacc 540
 tttgccgcaa gcctcgggtc gaaagttaac gccggacacg gtctgaccta tcacaacgtg 600
 aaagccattg ccgccatccc tgagatgcat gaactgaata tcggtcatgc cattattggt 660
 cgtgcagtga tgaccggact gaaagatgcg gtggcagaaa tgaagcgtct gatgctggaa 720
 gcgcgtggct aa 732

<210> 27

<211> 243

<212> PRT

<213> Escherichia coli

<400> 27

Met Ala Glu Leu Leu Leu Gly Val Asn Ile Asp His Ile Ala Thr Leu

1	5	10	15
Arg Asn Ala	Arg Gly Thr Ala Tyr	Pro Asp Pro Val Gln Ala Ala Phe	
	20	25	30
Ile Ala Glu	Gln Ala Gly Ala Asp Gly Ile Thr Val His Leu Arg Glu		
	35	40	45
Asp Arg Arg	His Ile Thr Asp Arg Asp Val Arg Ile Leu Arg Gln Thr		
	50	55	60
Leu Asp Thr	Arg Met Asn Leu Glu Met Ala Val Thr Glu Glu Met Leu		
65	70	75	80
Ala Ile Ala	Val Glu Thr Lys Pro His Phe Cys Cys Leu Val Pro Glu		
	85	90	95
Lys Arg Gln	Glu Val Thr Thr Glu Gly Gly Leu Asp Val Ala Gly Gln		
	100	105	110
Arg Asp Lys	Met Arg Asp Ala Cys Lys Arg Leu Ala Asp Ala Gly Ile		
	115	120	125
Gln Val Ser	Leu Phe Ile Asp Ala Asp Glu Glu Gln Ile Lys Ala Ala		
	130	135	140
Ala Glu Val	Gly Ala Pro Phe Ile Glu Ile His Thr Gly Cys Tyr Ala		
145	150	155	160
Asp Ala Lys	Thr Asp Ala Glu Gln Ala Gln Glu Leu Ala Arg Ile Ala		
	165	170	175
Lys Ala Ala	Thr Phe Ala Ala Ser Leu Gly Leu Lys Val Asn Ala Gly		
	180	185	190
His Gly Leu	Thr Tyr His Asn Val Lys Ala Ile Ala Ala Ile Pro Glu		
	195	200	205
Met His Glu	Leu Asn Ile Gly His Ala Ile Ile Gly Arg Ala Val Met		
	210	215	220
Thr Gly Leu	Lys Asp Ala Val Ala Glu Met Lys Arg Leu Met Leu Glu		
225	230	235	240
Ala Arg Gly			